image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
89b7ebafcef7fc23f1f5cc77421983398ab71210b224518d4df3232da5a25e53.png | simple | <table><tr><td>mRNA</td><td>Primer</td></tr><tr><td>Mouse B2m</td><td>Fwd 5′-ACCGTCTACTGGGATCGAGA-3′</td></tr><tr><td></td><td>Rev 5′-TGCTATTTCTTTCTGCGTGCAT-3′</td></tr><tr><td>Mouse Rpl13a</td><td>Fwd 5′-AGAAGCAGATCTTGAGGTTACGG-3′</td></tr><tr><td></td><td>Rev 5′-GTTCACACCAGGA... | <table><tr><td>mRNA</td></tr><tr><td>Mouse B2m</td></tr><tr><td></td></tr><tr><td>Mouse Rpl13a</td></tr><tr><td></td></tr><tr><td>Mouse Aqp5</td></tr><tr><td></td></tr><tr><td>Mouse T1α</td></tr><tr><td></td></tr><tr><td>Mouse Rage</td></tr><tr><td></td></tr><tr><td>Mouse Con43</td></tr><tr><td></td></tr><tr><td>Mouse ... | <table><tr><td>Primer</td></tr><tr><td>Fwd 5′-ACCGTCTACTGGGATCGAGA-3′</td></tr><tr><td>Rev 5′-TGCTATTTCTTTCTGCGTGCAT-3′</td></tr><tr><td>Fwd 5′-AGAAGCAGATCTTGAGGTTACGG-3′</td></tr><tr><td>Rev 5′-GTTCACACCAGGAGTCCGTT-3′</td></tr><tr><td>Fwd 5′-CTTGTGGGGATCTACTTCACCG-3′</td></tr><tr><td>Rev 5′-AAGTAGAGGATTGCAGCCAGG-3′</t... |
d25ab6b2494f868ba741ae8b4a7fa42019d4b5e4aa52428342c773e1a4f4b1ab.png | complex | <table><tr><td colspan="6">Base case ICER calculations</td><td colspan="4">Threshold analysis*: probability of cost-effective at alternative values of willingness to pay for a QALY(%)</td></tr><tr><td></td><td>Mean total cost (£)</td><td>Incremental cost (£)</td><td>Mean QALY</td><td>Incremental QALY</td><td>... | <table><tr><td colspan="6">Base case ICER calculations</td><td colspan="4">Threshold analysis*: probability of cost-effective at alternative values of willingness to pay for a QALY(%)</td></tr><tr><td></td><td>Mean total cost (£)</td><td>Incremental cost (£)</td><td>Mean QALY</td><td>Incremental QALY</td><td>ICER (£/QA... | <table><tr><td>Adjusted differences(95% CI; P-value)*</td><td>-2,047(-6,947 to 2,854; P = 0.413)</td><td>0.0431(-0.0171 to 0.1033; P = 0.161)</td></tr></table> |
46f82fc633f868703cb278df6103373cddce453cc70f48322af7aac7efc4d265.png | complex | <table><tr><td>Name</td><td>Sequence</td><td>Genome Position*</td><td>Expected Size (bp)</td><td>Reference</td></tr><tr><td>p20F</td><td>5' ACAATATGCGAGCTTACTTTA 3' </td><td>17691–17710</td><td rowspan="2">555</td><td rowspan="2">[18]</td></tr><tr><td>p20R</td><td>5' AACCTACACGCAAGATGGA 3' </td><td>18229–18... | <table><tr><td>Name</td><td>Sequence</td><td>Genome Position*</td><td>Expected Size (bp)</td><td>Reference</td></tr><tr><td>p20F</td><td>5' ACAATATGCGAGCTTACTTTA 3'</td><td>17691–17710</td><td rowspan="2">555</td><td rowspan="2">[18]</td></tr><tr><td>p20R</td><td>5' AACCTACACGCAAGATGGA 3'</td><td>18229–18246</td></tr><... | <table><tr><td>Name</td><td>Sequence</td><td>Genome Position*</td><td>Expected Size (bp)</td><td>Reference</td></tr><tr><td>p23F</td><td>5' GTCTCTCCATCTTGCGGTGTAG 3'</td><td>18224–18244</td><td rowspan="2">733</td><td rowspan="4">[30]</td></tr><tr><td>p23R</td><td>5' CAATCAGATGAAGTGGTG3'</td><td>18941–18957</td></tr><t... |
27b434f754ca7c8c8e229585a2f7665f51428473c8fd8a23b41926739772263b.png | simple | <table><tr><td>Plant material</td><td>Deposit number</td><td>Deposit location</td><td>Name of herbarium</td></tr><tr><td><i>Piper aduncum</i></td><td>10,480</td><td>INPA<sup>1</sup></td><td>INPA herbarium</td></tr><tr><td><i>Piper tuberculatum</i></td><td>6,797</td><td>IFAM<sup>2</sup></td><td>EAFM herbarium</td></tr><... | <table><tr><td>Plant material</td><td>Deposit number</td><td>Deposit location</td><td>Name of herbarium</td></tr><tr><td>Piper aduncum</td><td>10,480</td><td>INPA1</td><td>INPA herbarium</td></tr></table> | <table><tr><td>Piper tuberculatum</td><td>6,797</td><td>IFAM2</td><td>EAFM herbarium</td></tr><tr><td>Piper hispidum</td><td>6,796</td><td>IFAM</td><td>EAFM herbarium</td></tr><tr><td>Piper marginatum</td><td>6,798</td><td>IFAM</td><td>EAFM herbarium</td></tr><tr><td>Piper callosum</td><td>6,794</td><td>IFAM</td><td>EA... |
fa15271ec8771b01baa4864046acbc36f6388a434f83e40a09f2134102f2daa1.png | complex | <table><tr><td>Source</td><td><i>P</i></td><td></td><td rowspan="2">95% CI</td></tr><tr><td>Model</td><td>0.005</td><td>Odds Ratio</td></tr><tr><td>Diabetes Mellitus</td><td>0.017</td><td>1.823</td><td>1.111–2.99</td></tr><tr><td>Male Gender</td><td>0.048</td><td>0.616</td><td>0.381–0.998</td></tr><tr><td>C... | <table><tr><td>Source</td><td>P</td><td></td><td rowspan="2">95% CI</td></tr><tr><td>Model</td><td>0.005</td><td>Odds Ratio</td></tr><tr><td>Diabetes Mellitus</td><td>0.017</td><td>1.823</td><td>1.111–2.99</td></tr><tr><td>Male Gender</td><td>0.048</td><td>0.616</td><td>0.381–0.998</td></tr><tr><td>Chronic Heart Failur... | <table><tr><td>Liver disease</td><td>0.413</td><td>0.491</td><td>0.085–2.846</td></tr><tr><td>Lung disease</td><td>0.75</td><td>1.106</td><td>0.595–2.056</td></tr><tr><td>Ischaemic Heart Disease</td><td>0.944</td><td>1.022</td><td>0.559–1.869</td></tr></table> |
10862323c869c1eb1281ef215106b52eeeb6646a123076654dd5154c22468b2e.png | complex | <table><tr><td colspan="2">Annual drug expenses (USD) (n = 116), mean ± SD</td><td>T</td><td><i>p</i> value</td></tr><tr><td>Preoperative</td><td>660.08 ± 426.05</td><td rowspan="3">14.877</td><td rowspan="3"><0.001</td></tr><tr><td>Postoperative 1 year</td><td>65.12 ± 138.23</td></tr><tr><td>Differen... | <table><tr><td colspan="2">Annual drug expenses (USD) (n = 116), mean ± SD</td><td>T</td><td>p value</td></tr><tr><td>Preoperative</td><td>660.08 ± 426.05</td><td>14.877</td><td><0.001</td></tr></table> | <table><tr><td colspan="2">Annual drug expenses (USD) (n = 116), mean ± SD</td><td>T</td><td>p value</td></tr><tr><td>Postoperative 1 year</td><td>65.12 ± 138.23</td><td rowspan="2">14.877</td><td rowspan="2"><0.001</td></tr><tr><td>Difference in expenses</td><td>594.96 ± 430.74</td></tr></table> |
eaa5dd3fe3539338e7d23a7e535b2d51c6859ed46f2384ebe2361b4e73df1694.png | simple | <table><tr><td>ICD-10 code</td><td>Criteria for Appropriate Antibiotic Prescription</td></tr><tr><td>H65 Nonsuppurative otitis mediaH66 Suppurative and nonspecified otitis media</td><td>H65 must meet both conditions: presence of Acute Bilateral Otitis media AND age < 2H65 or H66 with presence of otorrhea</td></tr><t... | <table><tr><td>ICD-10 code</td><td>Criteria for Appropriate Antibiotic Prescription</td></tr></table> | <table><tr><td>H65 Nonsuppurative otitis mediaH66 Suppurative and nonspecified otitis media</td><td>H65 must meet both conditions: presence of Acute Bilateral Otitis media AND age < 2H65 or H66 with presence of otorrhea</td></tr><tr><td>J01 Acute sinusitis</td><td>Must meet all conditions: Fever of >38C°, purulent disc... |
8af24a21aeab8d3871795eb6cc31f1304ecf77318fd494ea169de01ffca32599.png | complex | <table><tr><td rowspan="2"> </td><td>Control</td><td colspan="3">JOAG</td><td colspan="3">AOAG</td></tr><tr><td>N (%)</td><td>N (%)</td><td>OR (95%CI)</td><td><i>P</i>*</td><td>N (%)</td><td>OR (95%CI)</td><td><i>P</i>*</td></tr><tr><td>Non-smoker</td><td>55 (43.7)</td><td>14 (41.2)</td><td>4.33 (0.12-5.84 × 10<su... | <table><tr><td rowspan="2"></td></tr><tr></tr><tr><td>Non-smoker</td></tr><tr><td>Smoker</td></tr></table> | <table><tr><td>Control</td><td colspan="3">JOAG</td><td colspan="3">AOAG</td></tr><tr><td>N (%)</td><td>N (%)</td><td>OR (95%CI)</td><td>P*</td><td>N (%)</td><td>OR (95%CI)</td><td>P*</td></tr><tr><td>55 (43.7)</td><td>14 (41.2)</td><td>4.33 (0.12-5.84 × 105)</td><td>0.692</td><td>31 (33.7)</td><td>1.03 (0.52-2.08)</td... |
4dcaea5ebb1eedc893e2c63b42d5e93d6d2318ea0248ddfab0261a47b49c28d2.png | simple | <table><tr><td>Preparedness</td><td>Female</td><td>Male</td></tr><tr><td>Personal:</td><td></td><td></td></tr><tr><td>Yes</td><td>8</td><td>19</td></tr><tr><td>No</td><td>11</td><td>7</td></tr><tr><td>Uncertain</td><td>3</td><td>4</td></tr><tr><td>Community: </td><td></td><td></td></tr><tr><td>Yes</td><td>5</td><td>5</... | <table><tr><td>Preparedness</td></tr><tr><td>Personal:</td></tr><tr><td>Yes</td></tr><tr><td>No</td></tr><tr><td>Uncertain</td></tr><tr><td>Community:</td></tr><tr><td>Yes</td></tr><tr><td>No</td></tr><tr><td>Uncertain / Improving</td></tr></table> | <table><tr><td>Female</td><td>Male</td></tr><tr><td></td><td></td></tr><tr><td>8</td><td>19</td></tr><tr><td>11</td><td>7</td></tr><tr><td>3</td><td>4</td></tr><tr><td></td><td></td></tr><tr><td>5</td><td>5</td></tr><tr><td>11</td><td>15</td></tr><tr><td>0</td><td>6</td></tr></table> |
e7018bb54696e2f3b56dc9b6fc6ee896255d97c61332dbf8872c8b7422a59ac4.png | complex | <table><tr><td rowspan="2">Filtered times</td><td colspan="3">Repeat</td><td colspan="2">Contigs (kb)</td><td colspan="3">Accuracy (%)</td><td rowspan="2">Genome coverage (%)</td></tr><tr><td>TRC</td><td>CNRC</td><td>NNC</td><td>N50</td><td>Max </td><td>CN-accuracy</td><td>Rep-accuracy</td><td>C-accuracy</td></tr><tr><... | <table><tr><td rowspan="2">Filtered times</td><td colspan="3">Repeat</td><td colspan="2">Contigs (kb)</td><td colspan="3">Accuracy (%)</td><td rowspan="2">Genome coverage (%)</td></tr><tr><td>TRC</td><td>CNRC</td><td>NNC</td><td>N50</td><td>Max</td><td>CN-accuracy</td><td>Rep-accuracy</td><td>C-accuracy</td></tr><tr><t... | <table><tr><td>3</td><td>13</td><td>Appendix</td><td>1025</td><td>0.3</td><td>2.3</td><td>100</td><td>68</td><td>100</td><td>77.4</td></tr></table> |
efb5e27aa44941aa87c0533fd9d52e4510583be182f892c43aa4e2e19a9f9ad6.png | simple | <table><tr><td></td><td>Synchronous combined surgery (<i>n</i> = 25) (35.7%)</td><td>Synchronous “bowel first” (<i>n</i> = 14) (20%)</td><td>Metachronous (<i>n</i> = 31) (44.3%)</td><td>Total (<i>n</i> = 70)</td><td><i>p</i> value</td></tr><tr><td>Age (years, range)</td><td>68 (34–85)</td><td>75 (46&#... | <table><tr><td></td><td>Synchronous combined surgery (n = 25) (35.7%)</td><td>Synchronous “bowel first” (n = 14) (20%)</td><td>Metachronous (n = 31) (44.3%)</td><td>Total (n = 70)</td><td>p value</td></tr><tr><td>Age (years, range)</td><td>68 (34–85)</td><td>75 (46–82)</td><td>70 (52–85)</td><td>69.5 (34–85)</td><td>0.... | <table><tr><td>Female</td><td>10 (40%)</td><td>5 (35.7%)</td><td>15 (48.4%)</td><td>30 (42.9%)</td><td></td></tr><tr><td>Bowel obstruction (n, %)</td><td>5 (20%)</td><td>7 (50%)</td><td>7 (22.6%)</td><td>19 (27.1%)</td><td>0.097</td></tr><tr><td>Site of primary tumor (n, %)</td><td></td><td></td><td></td><td></td><td>0... |
de317b6c8154376879e124fa267718fc4f27fd6b1587e1414ef3f466007d62a3.png | complex | <table><tr><td>Characteristics</td><td></td><td>Range</td></tr><tr><td>No. of patients</td><td>1085</td><td></td></tr><tr><td>Age, mean (SD)</td><td>44.72(12.12)</td><td>13-82</td></tr><tr><td>No. of women (%)</td><td colspan="2">846(77.97%)</td></tr><tr><td>Educational degree</td><td>Primary school</td><td>85</td></tr... | <table><tr><td>Characteristics</td></tr><tr><td>No. of patients</td></tr><tr><td>Age, mean (SD)</td></tr><tr><td>No. of women (%)</td></tr><tr><td>Educational degree</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr></table> | <table><tr><td></td><td>Range</td></tr><tr><td>1085</td><td></td></tr><tr><td>44.72(12.12)</td><td>13-82</td></tr><tr><td colspan="2">846(77.97%)</td></tr><tr><td>Primary school</td><td>85</td></tr><tr><td>Junior high</td><td>60</td></tr><tr><td>Senior high</td><td>211</td></tr><tr><td>College</td><td>576</td></tr><tr>... |
b012a742dd55296969a39542d0a03fd417a34d2799853a2c14ff39d044e65465.png | simple | <table><tr><td>Variable</td><td>HIV-negative</td><td>HIV-infected,</td><td>HIV-infected,</td></tr><tr><td>Proportion (%)</td><td>control</td><td>ART-naive</td><td>on ART</td></tr><tr><td>Median [IQR]</td><td>(number = 153)</td><td>(number = 151)</td><td>(number = 150)</td></tr><tr><td>Female</td><td>94 (61.4%)</td><td>... | <table><tr><td>Variable</td><td>HIV-negative</td><td>HIV-infected,</td><td>HIV-infected,</td></tr><tr><td>Proportion (%)</td><td>control</td><td>ART-naive</td><td>on ART</td></tr><tr><td>Median [IQR]</td><td>(number = 153)</td><td>(number = 151)</td><td>(number = 150)</td></tr><tr><td>Female</td><td>94 (61.4%)</td><td>... | <table><tr><td>ex (BMI) in kg/m2</td><td>25.8]</td><td>[20.2 to 24.3]</td><td>9]</td></tr><tr><td>BMI <18.5</td><td>5 (3.3%)</td><td>18 (11.9%)</td><td>4 (2.7%)</td></tr><tr><td>BMI 18.5 to 25</td><td>104 (68.0%)</td><td>113 (74.8%)</td><td>80 (53.3%)</td></tr><tr><td>BMI 25 to 30</td><td>33 (21.6%)</td><td>9 (6.0%)</t... |
c2e90abecc85b8a187fba02cdff32aa3705e8c047d18ffe346c56d28566de159.png | complex | <table><tr><td colspan="2"></td><td><i>N</i></td><td>Mean ± SD</td><td>Median</td><td>IQR</td><td>Range</td><td>β ± SE (p)</td></tr><tr><td rowspan="2">a)</td><td>Persisted to 2<sup>nd</sup> year</td><td>23</td><td>0·110 ± 0·068</td><td>0·105</td><td>0·061–0·139</td><t... | <table><tr><td colspan="2"></td><td>N</td><td>Mean ± SD</td><td>Median</td><td>IQR</td><td>Range</td><td>β ± SE (p)</td></tr><tr><td>a)</td><td>Persisted to 2nd year</td><td>23</td><td>0·110 ± 0·068</td><td>0·105</td><td>0·061–0·139</td><td>0·026–0·308</td><td>2·9 ± 3·7 (0·44)</td></tr></table> | <table><tr><td>a)</td><td>Did not persist</td><td>80</td><td>0·098 ± 0·060</td><td>0·089</td><td>0·065–0·117</td><td>0·000–0·301</td><td>2·9 ± 3·7 (0·44)</td></tr><tr><td rowspan="2">b)</td><td>Both adults survived</td><td>42</td><td>0·093 ± 0·067</td><td>0·082</td><td>0·048–0·117</td><td>0·000–0·308</td><td rowspan="2... |
a977a675cf70d54249794db2cfc9d40d3c7c00695423e815f078385e71238ef9.png | simple | <table><tr><td></td><td>Mean (mm)</td><td>Standard Deviation (mm)</td></tr><tr><td>Study I</td><td>0.43</td><td>3.54</td></tr><tr><td>Study II</td><td>‐1.77</td><td>5.23</td></tr></table> | <table><tr><td></td><td>Mean (mm)</td><td>Standard Deviation (mm)</td></tr></table> | <table><tr><td>Study I</td><td>0.43</td><td>3.54</td></tr><tr><td>Study II</td><td>‐1.77</td><td>5.23</td></tr></table> |
d1134fd1efe1c89edc6e4a9afc29798a41996aff10689b482269fe6a13654204.png | simple | <table><tr><td>Variable</td><td>Event</td><td>PYs</td><td>Rate</td><td>Crude HR (95% CI)</td><td>Adjusted HR (95% CI)</td></tr><tr><td>Comparison cohort</td><td>191</td><td>44535</td><td>42.89</td><td>ref</td><td>ref</td></tr><tr><td>OSA without treatment</td><td>62</td><td>6018</td><td>103.02</td><td>2.41 (1.81–... | <table><tr><td>Variable</td><td>Event</td><td>PYs</td><td>Rate</td><td>Crude HR (95% CI)</td><td>Adjusted HR (95% CI)</td></tr></table> | <table><tr><td>Comparison cohort</td><td>191</td><td>44535</td><td>42.89</td><td>ref</td><td>ref</td></tr><tr><td>OSA without treatment</td><td>62</td><td>6018</td><td>103.02</td><td>2.41 (1.81–3.21)</td><td>2.15 (1.60–2.88)</td></tr><tr><td>OSA with surgery only</td><td>7</td><td>1407</td><td>49.75</td><td>1.15 (0.54–... |
d073b9d38365dbea97684baae06f017b077f40e19b893e1d8b1cd08390c1c3ba.png | complex | <table><tr><td>Cox regression</td><td colspan="2">Crude analysis</td><td colspan="2">Adjusted analysis</td></tr><tr><td>Variable</td><td><i>RR</i></td><td>95% CI</td><td><i>RR</i></td><td>95% CI</td></tr><tr><td><i>Sex</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Female</td><td>1</td><td></td><td>1</td><td... | <table><tr><td>Cox regression</td><td colspan="2">Crude analysis</td><td>Adjusted analysis</td></tr><tr><td>Variable</td><td>RR</td><td>95% CI</td><td>RR</td></tr><tr><td>Sex</td><td></td><td></td><td></td></tr><tr><td>Female</td><td>1</td><td></td><td>1</td></tr><tr><td>Male</td><td>1.48</td><td>0.80-2.74</td><td>1.50... | <table><tr><td>Adjusted analysis</td></tr><tr><td>95% CI</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>0.81-2.79</td></tr><tr><td>1.01-1.05</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>0.46-1.57</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></t... |
d93288de5ac4a75e1247607ec90b979a5ba54914b5b73cbdbe39776461cc94a0.png | complex | <table><tr><td colspan="2"><underline>TOP10 with pLC-T4LysHeat</underline></td></tr><tr><td>Lysis entity in exponential phase [%]</td><td>73 ± 0.3</td></tr><tr><td>Lysis delay after induction [min]</td><td>55</td></tr><tr><td>Doubling time [min]</td><td>66.1 ± 1.7</td></tr><tr><td>Doubling time of negative co... | <table><tr><td colspan="2">TOP10 with pLC-T4LysHeat</td></tr></table> | <table><tr><td>Lysis entity in exponential phase [%]</td><td>73 ± 0.3</td></tr><tr><td>Lysis delay after induction [min]</td><td>55</td></tr><tr><td>Doubling time [min]</td><td>66.1 ± 1.7</td></tr><tr><td>Doubling time of negative control [min]</td><td>65.9 ± 0.6</td></tr></table> |
a3f85133fa8a27004872621fc496947a9050f3ba6b71f69936f307c596bdb382.png | complex | <table><tr><td rowspan="2">Effects (% Substitution)</td><td colspan="2">Peak 1 (cP)</td><td colspan="2">Trough 1 (Nm)</td><td colspan="2">Break Down</td><td colspan="2">Final Visc <sup>3</sup> (cP)</td><td colspan="2">Setback (cP)</td><td colspan="2">Peak Time (min)</td><td colspan="2">Pasting Temp (°C)</td></tr><... | <table><tr><td rowspan="2">Effects (% Substitution)</td><td colspan="2">Peak 1 (cP)</td><td colspan="2">Trough 1 (Nm)</td><td colspan="2">Break Down</td><td colspan="2">Final Visc 3 (cP)</td><td colspan="2">Setback (cP)</td><td colspan="2">Peak Time (min)</td><td colspan="2">Pasting Temp (°C)</td></tr><tr><td>Mean</td>... | <table><tr><td rowspan="2">Effects (% Substitution)</td><td colspan="2">Peak 1 (cP)</td><td colspan="2">Trough 1 (Nm)</td><td colspan="2">Break Down</td><td colspan="2">Final Visc 3 (cP)</td><td colspan="2">Setback (cP)</td><td colspan="2">Peak Time (min)</td><td colspan="2">Pasting Temp (°C)</td></tr><tr><td>Mean</td>... |
e87bba5267499998e22dc7e6b826adea9c0d3ff1a843f8ea24b55db5dea6fd86.png | simple | <table><tr><td>Gene</td><td>Primer sequence</td></tr><tr><td>Collagen II</td><td>Forward primer 5′‐GCTCCCAGAACATCACCTACCA‐3′Reverse primer 5′‐ACAGTCTTGCCCCACTTACCG‐3′</td></tr><tr><td>Aggrecan</td><td>Forward primer 5′‐AGGTCGTGGTGAAAGGTGTTGTG‐3′Rev... | <table><tr><td>Gene</td><td>Primer sequence</td></tr><tr><td>Collagen II</td><td>Forward primer 5′‐GCTCCCAGAACATCACCTACCA‐3′Reverse primer 5′‐ACAGTCTTGCCCCACTTACCG‐3′</td></tr><tr><td>Aggrecan</td><td>Forward primer 5′‐AGGTCGTGGTGAAAGGTGTTGTG‐3′Reverse primer 5′‐TGGTGGAAGCCATCCTCGTAG‐3′</td></tr><tr><td>Sox‐9</td><td>F... | <table><tr><td>Gene</td><td>Primer sequence</td></tr><tr><td></td><td>‐ GCACCAGCGTCCAGTCGTA‐3′</td></tr><tr><td>Collagen X</td><td>Forward primer 5′‐GCCCTTCTGCTGCTAGTGTCTTT‐3′Reverse primer 5′‐TGTGTCTTGGTGTTGGGTTGTG‐3′</td></tr><tr><td>GAPDH</td><td>Forward primer 5′‐AAGGTCGGAGTGAACGGATTTG‐3′Reverse primer 5′‐CGTGGGTGG... |
b5060c7db73e921cfbb38edc42c0541cfebc0ac7670f6c4def7f531b3c289e2b.png | simple | <table><tr><td>Plant species</td><td>Degree of inhibition</td></tr><tr><td><i>Andrographis paniculata</i></td><td>+++</td></tr><tr><td><i>Momordica charantia</i></td><td>++</td></tr><tr><td><i>Cymbopogn citratus</i></td><td>+</td></tr><tr><td><i>Ocimum sanctum</i></td><td>+</td></tr><tr><td><i>Citrus limon</i></td><td>... | <table><tr><td>Plant species</td><td>Degree of inhibition</td></tr><tr><td>Andrographis paniculata</td><td>+++</td></tr><tr><td>Momordica charantia</td><td>++</td></tr><tr><td>Cymbopogn citratus</td><td>+</td></tr><tr><td>Ocimum sanctum</td><td>+</td></tr><tr><td>Citrus limon</td><td>-</td></tr></table> | <table><tr><td>Plant species</td><td>Degree of inhibition</td></tr><tr><td>Pelargonium citrosum</td><td>-</td></tr></table> |
a16cd6aa272f9928b6da8825cf8d56e473e9419a97da1e2ab52f06a4bafc4b11.png | complex | <table><tr><td>HCV Genotype</td><td colspan="2">Modified Multiplex PCR Method (Genotype Specific Primers)</td><td colspan="2">INNO-LiPA HCV II (Line Probe Assay)</td></tr><tr><td></td><td>Isolates, No.</td><td>Percentage</td><td>Isolates, No.</td><td>Percentage</td></tr><tr><td>1a</td><td>1</td><td>1.37</td><td>1</td><... | <table><tr><td>HCV Genotype</td><td colspan="2">Modified Multiplex PCR Method (Genotype Specific Primers)</td><td>INNO-LiPA HCV II (Line Probe Assay)</td></tr><tr><td></td><td>Isolates, No.</td><td>Percentage</td><td>Isolates, No.</td></tr><tr><td>1a</td><td>1</td><td>1.37</td><td>1</td></tr><tr><td>1b</td><td>1</td><t... | <table><tr><td>INNO-LiPA HCV II (Line Probe Assay)</td></tr><tr><td>Percentage</td></tr><tr><td>1.37</td></tr><tr><td>1.37</td></tr><tr><td>4.11</td></tr><tr><td>52.05</td></tr><tr><td>2.74</td></tr><tr><td>24.66</td></tr><tr><td>6.85</td></tr><tr><td>5.48</td></tr><tr><td>1.37</td></tr><tr><td>100</td></tr></table> |
437d2e2d5d21cd5f910ad2eeaf4abe5ea0ea71055e90752e626e61fd9b5882f7.png | complex | <table><tr><td>Characteristics</td><td>Frequency</td><td>Percentage</td></tr><tr><td colspan="3">Sex</td></tr><tr><td> Male</td><td>482</td><td>53.8</td></tr><tr><td> Female</td><td>414</td><td>46.2</td></tr><tr><td colspan="3">Religion</td></tr><tr><td> Christianity</td><td>888</td><td>99.1</td></tr><tr><td> Islam</td... | <table><tr><td>Characteristics</td><td>Frequency</td><td>Percentage</td></tr><tr><td colspan="3"></td></tr></table> | <table><tr><td colspan="3">Sex</td></tr><tr><td>Male</td><td>482</td><td>53.8</td></tr><tr><td>Female</td><td>414</td><td>46.2</td></tr><tr><td colspan="3">Religion</td></tr><tr><td>Christianity</td><td>888</td><td>99.1</td></tr><tr><td>Islam</td><td>6</td><td>0.7</td></tr><tr><td>Traditional African Religion</td><td>2... |
041b4619697c8dfa0a851cde04ce29a16d6b3ba003cbecbffc01ffea515aa627.png | complex | <table><tr><td>Sample</td><td colspan="3">Wild type CHO-S crude protein extract</td><td colspan="3">pcDNA: <i>trp-2</i><sub><i>1-472</i></sub><i>-cA</i> transfected CHO-S cell crude protein extract</td></tr><tr><td>Replicates</td><td>1</td><td>2</td><td>3</td><td>1</td><td>2</td><td>3</td></tr><tr><td>0 min</td><td>0.2... | <table><tr><td>Sample</td><td colspan="3">Wild type CHO-S crude protein extract</td><td colspan="3">pcDNA: trp-21-472-cA transfected CHO-S cell crude protein extract</td></tr><tr><td>Replicates</td><td>1</td><td>2</td><td>3</td><td>1</td><td>2</td><td>3</td></tr><tr><td>0 min</td><td>0.203</td><td>0.205</td><td>0.202</... | <table><tr><td>Sample</td><td colspan="3">Wild type CHO-S crude protein extract</td><td colspan="3">pcDNA: trp-21-472-cA transfected CHO-S cell crude protein extract</td></tr><tr><td>Replicates</td><td>1</td><td>2</td><td>3</td><td>1</td><td>2</td><td>3</td></tr><tr><td>5 mins</td><td>0.196</td><td>0.199</td><td>0.194<... |
3a06679ac46b86a6deb063bd49020075e5da2ebe8ec8473f6ac3154ead8dd21e.png | complex | <table><tr><td>Parameters</td><td>Hazard ratio</td><td>95% confidence interval</td><td>P value</td></tr><tr><td colspan="4">5-year-DFS</td></tr><tr><td>EZH2</td><td>2.287</td><td>1.137-4.602</td><td>0.020</td></tr><tr><td>pT</td><td>2.244</td><td>1.076-4.678</td><td>0.013</td></tr><tr><td>pN</td><td>2.532</td><td>1.292... | <table><tr><td>Parameters</td><td>Hazard ratio</td><td>95% confidence interval</td><td>P value</td></tr><tr><td colspan="4">5-year-DFS</td></tr><tr><td>EZH2</td><td>2.287</td><td>1.137-4.602</td><td>0.020</td></tr><tr><td>pT</td><td>2.244</td><td>1.076-4.678</td><td>0.013</td></tr><tr><td>pN</td><td>2.532</td><td>1.292... | <table><tr><td>pN</td><td>2.471</td><td>1.138-5.364</td><td>0.022</td></tr></table> |
a7180054a0946746b05092e3c266b62db9e6aeba4f7fda1343f5bd3cc1c2a91d.png | complex | <table><tr><td>Variable</td><td></td><td>Men (<i>n</i> = 21)</td><td>Women (<i>n</i> = 19)</td><td>Total (<i>n</i> = 40)</td></tr><tr><td rowspan="2">Glucose (mg/dL)</td><td>Week 0</td><td>103.3 ± 5.0</td><td>96.4 ± 3.3</td><td>99.8 ± 3.0</td></tr><tr><td>Week 12 <sup>a</sup></td><td>91.3 ± 2.1</td>... | <table><tr><td>Variable</td><td></td><td>Men (n = 21)</td><td>Women (n = 19)</td><td>Total (n = 40)</td></tr><tr><td></td><td>Wee</td><td>10</td><td>96.4 ±</td><td></td></tr></table> | <table><tr><td>Variable</td><td></td><td>Men (n = 21)</td><td>Women (n = 19)</td><td>Total (n = 40)</td></tr><tr><td rowspan="2">Glucose (mg/dL)</td><td>k 0</td><td>3.3 ± 5.0</td><td> 3.3</td><td>99.8 ± 3.0</td></tr><tr><td>Week 12 a</td><td>91.3 ± 2.1</td><td>89.8 ± 2.3</td><td>90.5 ± 1.5</td></tr><tr><td rowspan="2">... |
ef75d19174432833e30058da061237a6dbe909ce20fc029db7f574db55e4ea9f.png | complex | <table><tr><td rowspan="2">Mixture</td><td colspan="5">Compressive Strength (MPa) *</td></tr><tr><td>3 Days</td><td>7 Days</td><td>14 Days</td><td>28 Days</td><td>90 Days</td></tr><tr><td>C-0.45-N</td><td>30.74 <i>0.77</i></td><td>41.93 <i>0.67</i></td><td>49.17 <i>1.40</i></td><td>56.93 <i>0.81</i></td><td>65.98 <i>0.... | <table><tr><td rowspan="2">Mixture</td><td>Compressive Strength (MPa) *</td></tr><tr><td>3 Days</td></tr><tr><td>C-0.45-N</td><td>30.74 0.77</td></tr><tr><td>C-0.45-H</td><td>34.79 0.63</td></tr><tr><td>C-0.45-SCM</td><td>40.76 0.68</td></tr><tr><td>10FA-0.45-N</td><td>31.77 2.41</td></tr><tr><td>10FA-0.45-H</td><td>33... | <table><tr><td colspan="4">Compressive Strength (MPa) *</td></tr><tr><td>7 Days</td><td>14 Days</td><td>28 Days</td><td>90 Days</td></tr><tr><td>41.93 0.67</td><td>49.17 1.40</td><td>56.93 0.81</td><td>65.98 0.92</td></tr><tr><td>45.82 0.89</td><td>54.43 0.17</td><td>61.72 1.67</td><td>69.73 0.42</td></tr><tr><td>48.95... |
2495d649d7b25b964991797f45e43c9d48ee97c4066b6018414be9b9c77f1a14.png | complex | <table><tr><td rowspan="2">Groups</td><td rowspan="2">Dose (TCID50) 1 mL</td><td colspan="9">Survival rate (day post infection)</td><td rowspan="2">Mortality (%)</td></tr><tr><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td><td>11</td><td>12</td><td>13</td><td>14</td></tr><tr><td>PRV FJ-2012</td><td>10<sup>6</sup></t... | <table><tr><td rowspan="2">Groups</td><td rowspan="2">Dose (TCID50) 1 mL</td><td colspan="9">Survival rate (day post infection)</td><td rowspan="2">Mortality (%)</td></tr><tr><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td><td>11</td><td>12</td><td>13</td><td>14</td></tr><tr><td>PRV FJ-2012</td><td>106</td><td>4/4</... | <table><tr><td rowspan="2">Groups</td><td rowspan="2">Dose (TCID50) 1 mL</td><td colspan="9">Survival rate (day post infection)</td><td rowspan="2">Mortality (%)</td></tr><tr><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td><td>11</td><td>12</td><td>13</td><td>14</td></tr><tr><td>Control</td><td>DMEM</td><td>4/4</td>... |
fdb7954d71f521fe84bf28ee5c31d4d09a9b3cc9b2931b1d08bf8078ca9aee65.png | simple | <table><tr><td>Supplementary addition of L- proline (mM)</td><td>0</td><td>1</td><td>2</td><td>4</td><td>8</td><td>12</td></tr><tr><td>Hyp (g/L)</td><td>2.28</td><td>2.81</td><td>3.25</td><td>6.72</td><td>5.56</td><td>6.32</td></tr></table> | <table><tr><td>Supplementary addition of L- proline (mM)</td><td>0</td><td>1</td><td>2</td><td>4</td><td>8</td><td>12</td></tr><tr><td>Hyp (g/</td><td>2.2</td><td>2.8</td><td>3</td><td>6.</td><td>5</td><td>6.32</td></tr></table> | <table><tr><td>L)</td><td>8</td><td>1</td><td>.25</td><td>72</td><td>.56</td><td></td></tr></table> |
f8fece1034fbae35d4988c512295c4e52061040687f81fc367691c0723c11f2f.png | complex | <table><tr><td rowspan="2">Treatment</td><td colspan="2">Open dentinal tubules (N/mm<sup>2</sup>) (N=20)</td><td colspan="2">Diameter of tubules (μm) (N=20)</td></tr><tr><td>Old root </td><td>Young root </td><td>Old root </td><td>Young root </td></tr><tr><td>Citric acid</td><td>122 (14) </td><td>152 (19) </td><td>... | <table><tr><td>Treatment</td><td colspan="2">Open dentinal tubules (N/mm2) (N=20)</td><td colspan="2">Diameter of tubules (μm) (N=20)</td></tr></table> | <table><tr><td>Treatment</td><td>Old root</td><td>Young root</td><td>Old root</td><td>Young root</td></tr><tr><td>Citric acid</td><td>122 (14)</td><td>152 (19)</td><td>2.0 (0.1)</td><td>1.7 (0.2)</td></tr><tr><td>EDTA</td><td>161 (22)</td><td>140 (17)</td><td>2.3 (0.1)</td><td>1.7 (0.2) a</td></tr><tr><td>Control</td><... |
1b2e55d6bedda37626738e6b215c545b3af16336ed4ceccf0f528592ac53c7b6.png | simple | <table><tr><td>SOUND CATEGORY</td><td>DESCRIPTION</td></tr><tr><td>Mouth</td><td>Crunching a hard candy</td></tr><tr><td></td><td>Kissing</td></tr><tr><td></td><td>Gargling</td></tr><tr><td></td><td>Crunching chips</td></tr><tr><td></td><td>Finishing a beverage with a straw</td></tr><tr><td>Hand</td><td>Ripping a sheet... | <table><tr><td>SOUND CATEGORY</td><td>DESCRIPTION</td></tr><tr><td>Mouth</td><td>Crunching a hard candy</td></tr><tr><td></td><td>Kissing</td></tr><tr><td></td><td>Gargling</td></tr><tr><td></td><td>Crunching chips</td></tr><tr><td></td><td>Finishing a beverage with a straw</td></tr><tr><td>Hand</td><td>Ripping a sheet... | <table><tr><td>DESCRIPTION</td></tr><tr><td>Gargle</td></tr><tr><td>Straw</td></tr></table> |
6da5c2e2c89fa59661c9e439af6549b0c485b558b3f8f6b8a71ec53d4e877912.png | simple | <table><tr><td>DNA sequence</td><td>A</td><td>T</td><td>G</td><td>C</td><td>G</td><td>A</td><td>C</td><td>C</td><td>C</td><td>T...</td></tr><tr><td><i>x</i><sub><i>A</i></sub>(<i>k</i>):</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><i>x</i><sub><i>... | <table><tr><td>DNA sequence</td><td>A</td><td>T</td><td>G</td><td>C</td><td>G</td><td>A</td><td>C</td><td>C</td><td>C</td><td>T...</td></tr><tr><td>xA(k):</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>xC(k):</td><td>0</td><td>0</td><td>0</td><td>1</... | <table><tr><td>xG(k):</td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>xT(k):</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td></tr></table> |
4ab9d0e98022c5e4078b1216ce15b76556bc0815656a0a3abf51d805c3076a22.png | complex | <table><tr><td>Antigen</td><td colspan="2">Antibody</td><td>Crude IRR (95%CI)</td><td>P-value</td><td>Age-adjusted IRR</td><td>P-value</td></tr><tr><td>MSP3</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>IgG2*</td><td>(coded as log(2))</td><td>0.74 (0.57, 0.98)</td><td>0.04</td><td>0.85... | <table><tr><td>Antigen</td><td colspan="2">Antibody</td><td>Crude IRR (95%CI)</td><td>P-value</td><td>Age-adjusted IRR</td><td>P-value</td></tr><tr><td>MSP3</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> | <table><tr><td>Antigen</td><td colspan="2">Antibody</td><td>Crude IRR (95%CI)</td><td>P-value</td><td>Age-adjusted IRR</td><td>P-value</td></tr><tr><td></td><td>IgG2*</td><td>(coded as log(2))</td><td>0.74 (0.57, 0.98)</td><td>0.04</td><td>0.85 (0.63, 1.15)</td><td>0.29</td></tr><tr><td></td><td>IgG4</td><td>< detectio... |
67dc30b63d5d5d9e0d2430a57b54465ad9ddef64ed544397330a751bd0d3f3c3.png | simple | <table><tr><td></td><td>CEER</td><td>Reverse Phase Protein Array</td><td>PhosphoFlow</td><td>ELISA</td></tr><tr><td>Sample Protein Requirement</td><td>Native proteins</td><td>Denatured proteins</td><td>Fixed proteins</td><td>Native or Fixed proteins</td></tr><tr><td>Minimum Cell Requirement (Assay Sensitivity)</td><td>... | <table><tr><td></td><td>CEER</td><td>Reverse Phase Protein Array</td><td>PhosphoFlow</td><td>ELISA</td></tr><tr><td>Sample Protein Requirement</td><td>Native proteins</td><td>Denatured proteins</td><td>Fixed proteins</td><td>Native or Fixed proteins</td></tr><tr><td>Minimum Cell Requirement (Assay Sensitivity)</td><td>... | <table><tr><td>Disadvantages of Assay</td><td>• Screening compatible antibody sets for each target.</td><td>• Need to print each sample; not suitable for applications in clinical samples from individual patients.• Cross reaction of detector antibody.</td><td>• Not suitable for rare cell analysis or solid tissue samples... |
eac3b643a3f6d4b263d8bd1d4414ac09d799d2171d826e5330e684f767bbd3ac.png | simple | <table><tr><td></td><td>Sensitivity</td><td>Specificity</td><td>Positive Predictive Value</td><td>Negative Predictive Value</td></tr><tr><td>PF/other<sup>1</sup>(PF gametocytaemia considered negative for PF)</td><td>89.1[85.5-91.8]</td><td>97.6[96.5-98.4]</td><td>93.8[90.8-95.9]</td><td>95.2[94.2-96.8]</td></tr><tr><td... | <table><tr><td></td><td>Sensitivity</td><td>Specificity</td><td>Positive Predictive Value</td><td>Negative Predictive Value</td></tr><tr><td>PF/other1(PF gametocytaemia considered negative for PF)</td><td>89.1[85.5-91.8]</td><td>97.6[96.5-98.4]</td><td>93.8[90.8-95.9]</td><td>95.2[94.2-96.8]</td></tr><tr><td>PF/other2(... | <table><tr><td>PF mono-infection2(PF gametocytaemia considered positive for PF)</td><td>86.7[79.9-91.4]</td><td>-</td><td>-</td><td>-</td></tr><tr><td>PV mono-infection1(PV gametocytaemia considered negative for PV)</td><td>91.0[86.5-94.1]</td><td>-</td><td>-</td><td>-</td></tr><tr><td>PV mono-infection2(PV gametocytae... |
70eae41057f2ca1244fd26c21d91de9723cfae7eabd4c1bdbad266513a6f92e8.png | simple | <table><tr><td>ORF</td><td>Gene</td><td>Identification</td><td>Genotype used in this study</td></tr><tr><td>F17A2.5</td><td><i>ceh-40</i></td><td>Homeodomain protein (<i>Extradenticle </i>ortholog)</td><td><i>ceh-40(ok740) </i>X</td></tr><tr><td>K10B4.6</td><td><i>cwn-1</i></td><td>Putative Wnt ligand</td><td><i>cwn-1(... | <table><tr><td>ORF</td><td>Gene</td><td>Identification</td></tr><tr><td>F17A2.5</td><td>ceh-40</td><td>Homeodomain protein (Extradenticle ortholog)</td></tr><tr><td>K10B4.6</td><td>cwn-1</td><td>Putative Wnt ligand</td></tr><tr><td>D1081.2</td><td>unc-120</td><td>MADS domain TF</td></tr><tr><td>B0304.1</td><td>hlh-1</t... | <table><tr><td>Genotype used in this study</td></tr><tr><td>ceh-40(ok740) X</td></tr><tr><td>cwn-1(ok546) II</td></tr><tr><td>unc-120(st364) I</td></tr><tr><td>hlh-1(cc561) II</td></tr><tr><td>hnd-1(q740) X</td></tr><tr><td>mab-21(bx53)III; him-5(e1490)V</td></tr><tr><td>+/szT1 [lon-2(e678)] I; nhr-25(jm2389)/szT1 X</t... |
4a7a7321f00d60085cb9e795afddca720a6ab777144998290dfd65bf90acf62d.png | simple | <table><tr><td>Variables</td><td>R</td><td><i>p</i>-Value **</td></tr><tr><td>Socioeconomic</td><td></td><td></td></tr><tr><td>Age (years)</td><td>0.125</td><td>0.243</td></tr><tr><td>Schooling (years)</td><td>0.118</td><td>0.267</td></tr><tr><td>Per capita income (real)</td><td>−0.080</td><td>0.441</td></tr><tr>... | <table><tr><td>Variables</td><td>R</td><td>p-Value **</td></tr><tr><td>Socioeconomic</td><td></td><td></td></tr><tr><td>Age (years)</td><td>0.125</td><td>0.243</td></tr><tr><td>Schooling (years)</td><td>0.118</td><td>0.267</td></tr><tr><td>Per capita income (real)</td><td>−0.080</td><td>0.441</td></tr><tr><td>Water sup... | <table><tr><td>Variables</td><td>R</td><td>p-Value **</td></tr><tr><td>Garbage collection</td><td>0.008</td><td>0.935</td></tr><tr><td>Sewer connect to the public network or existence of septic tank</td><td>0.162</td><td>0.128</td></tr><tr><td>Basic sanitation</td><td>0.226</td><td>0.033</td></tr><tr><td>Obstetric</td>... |
c79ad6458404b28e44e62c2a10d454242c39bb1ebac5f41c9094be48b00afac2.png | simple | <table><tr><td>Summary of progress with IRS and ITNs</td><td>MIS 2006</td><td>MIS 2008</td><td>MIS 2010</td></tr><tr><td>Percentage of households receiving indoor residual spraying (IRS) in the previous 12 months among all households</td><td>9.5</td><td>14.9</td><td>23.1</td></tr><tr><td>Percentage of household members... | <table><tr><td>Summary of progress with IRS and ITNs</td><td>MIS 2006</td><td>MIS 2008</td><td>MIS 2010</td></tr><tr><td>Percentage of households receiving indoor residual spraying (IRS) in the previous 12 months among all households</td><td>9.5</td><td>14.9</td><td>23.1</td></tr><tr><td>Percentage of household members... | <table><tr><td>Summary of progress with IRS and ITNs</td><td>MIS 2006</td><td>MIS 2008</td><td>MIS 2010</td></tr><tr><td>Percentage of children ages 0–59 months who slept under an ITN the previous night</td><td>24</td><td>41</td><td>50</td></tr><tr><td>Percentage of children ages 0–59 months with malaria parasitaemia</... |
a8a07fae4b08f0ccff02f65ee375fa0f0b4eb66c17d4926b3131c22166b67d48.png | complex | <table><tr><td></td><td colspan="3">Factors</td></tr><tr><td>Self-assessment item</td><td>1</td><td>2</td><td>3</td></tr><tr><td>1) Obtain a medical history that is relevant to the patient's complaint</td><td>0.83</td><td></td><td></td></tr><tr><td>2) Perform a clinical examination that is targeted at the patient's chi... | <table><tr><td></td><td colspan="3">Factors</td></tr><tr><td>Self-assessment item</td><td>1</td><td>2</td><td>3</td></tr><tr><td>1) Obtain a medical history that is relevant to the patient's complaint</td><td>0.83</td><td></td><td></td></tr><tr><td>2) Perform a clinical examination that is targeted at the patient's chi... | <table><tr><td></td><td colspan="3">Factors</td></tr><tr><td>8) Discuss a patient's religious preferences and constraints regarding his treatment</td><td></td><td>0.73</td><td></td></tr><tr><td>9) Communicate the importance of medical treatment to a patient who believes that his illness is due to supernatural causes</t... |
0e5fa58216c06131acbcc20995885da3160007cdb3225776070b91c987ff22a6.png | simple | <table><tr><td>Group</td><td>nNOS activity (nmol/min/mg)</td><td>MDA nmol/g/wet tissue</td><td>GSH nmol/g/wet tissue</td></tr><tr><td>Control</td><td>0.604 ± 0.04</td><td>3.55 ± 0.20</td><td>1.68 ± 0.15</td></tr><tr><td>Cocaine</td><td>0.935 ± 0.14<sup>*</sup></td><td>4.65 ± 0.32<sup>*</sup></t... | <table><tr><td>Group</td><td>nNOS activity (nmol/min/mg)</td><td>MDA nmol/g/wet tissue</td><td>GSH nmol/g/wet tissue</td></tr><tr><td>Control</td><td>0.604 ± 0.04</td><td>3.55 ± 0.20</td><td>1.68 ± 0.15</td></tr><tr><td>Cocaine</td><td>0.935 ± 0.14*</td><td>4.65 ± 0.32*</td><td>0.94 ± 0.10*</td></tr><tr><td>7-N</td><td... | <table><tr><td>I</td><td>0.360 ± 0.07*</td><td></td><td>0</td></tr><tr><td>7-NI + cocaine</td><td>0.535 ± 0.10+</td><td>3.68 ± 0.15+</td><td>1.55 ± 0.08+</td></tr></table> |
55af6ae76a25d9bd53d90fa739e9c042881b4cda1e116a403093719b3350e123.png | complex | <table><tr><td>Parameters</td><td>Base-case</td><td>Range (min—max)</td><td>Reference</td></tr><tr><td>Thai birth cohort population</td><td>782,129</td><td>–</td><td>(19)</td></tr><tr><td>Incidence of haemophilus influenzae type b (Hib) meningitis in <1 year old</td><td>0.000137</td><td>0.000038–0.... | <table><tr><td>Parameters</td><td>Base-case</td><td>Range (min—max)</td><td>Reference</td></tr><tr><td>Thai birth cohort population</td><td>782,129</td><td>–</td><td>(19)</td></tr><tr><td>Incidence of haemophilus influenzae type b (Hib) meningitis in <1 year old</td><td>0.000137</td><td>0.000038–0.000236</td><td rowspa... | <table><tr><td>Parameters</td><td>Base-case</td><td>Range (min—max)</td><td>Reference</td></tr><tr><td>Epilepsy</td><td>1.005</td><td>1.000–1.010</td><td>(24)</td></tr><tr><td>Developmental deficit</td><td>6.165</td><td>5.160–7.170</td><td></td></tr></table> |
50d45d0e1b6ccb3890ae28abb714eb91982520b5aae56700ececa50aa88f1d39.png | complex | <table><tr><td rowspan="2">Annual average</td><td colspan="3">Primary care utilisation</td><td colspan="3">95% confidence interval</td><td colspan="2">Reduction</td></tr><tr><td>Low (n = 6987)</td><td>Medium (n = 5926)</td><td>High (n = 1271)</td><td>Low</td><td>Medium</td><td>High</td><td>Medium</td><td>High</td></tr>... | <table><tr><td rowspan="2">Annual average</td><td colspan="3">Primary care utilisation</td><td colspan="3">95% confidence interval</td><td colspan="2">Reduction</td></tr><tr><td>Low (n = 6987)</td><td>Medium (n = 5926)</td><td>High (n = 1271)</td><td>Low</td><td>Medium</td><td>High</td><td>Medium</td><td>High</td></tr>... | <table><tr><td rowspan="2">Annual average</td><td colspan="3">Primary care utilisation</td><td colspan="3">95% confidence interval</td><td colspan="2">Reduction</td></tr><tr><td>Low (n = 6987)</td><td>Medium (n = 5926)</td><td>High (n = 1271)</td><td>Low</td><td>Medium</td><td>High</td><td>Medium</td><td>High</td></tr>... |
c3edf7f07e71984efd3e6945369cc62df4fcb3eb45a0bd0993941391cc2f0198.png | simple | <table><tr><td>Clinical features</td><td>FA</td><td>XP</td><td>CS</td><td>TTD</td></tr><tr><td>Cancer</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td>Skin pigmentation</td><td>+</td><td>+</td><td>-</td><td>±</td></tr><tr><td>Developmental delay</td><td>+</td><td>-</td><td>+</td><td>+</td></tr><tr><td>Neur... | <table><tr><td>Clinical features</td><td>FA</td><td>XP</td><td>CS</td><td>TTD</td></tr><tr><td>Cancer</td><td>+</td><td>+</td><td>-</td><td>-</td></tr></table> | <table><tr><td>Clinical features</td><td>FA</td><td>XP</td><td>CS</td><td>TTD</td></tr><tr><td>Skin pigmentation</td><td>+</td><td>+</td><td>-</td><td>±</td></tr><tr><td>Developmental delay</td><td>+</td><td>-</td><td>+</td><td>+</td></tr><tr><td>Neurological defects</td><td>±</td><td>±</td><td>+</td><td>+</td></tr></t... |
ea82c1d04c5a58b870ab9002df51197ce488b73c5e16e0cbd7e259efb6f79531.png | simple | <table><tr><td>Operational Mode</td><td>bits/s</td><td>kbits/sol</td><td>Power(mW)</td><td>Energy/sol(mWh)</td></tr><tr><td>Nominal (1sps during 5 min each hour)</td><td>112</td><td>806.4</td><td>0.25</td><td>0.5</td></tr><tr><td>In-flight calibration (1sps during 15 min each week)</td><td>112</td><td>14.4</td><td>500<... | <table><tr><td>Operational Mode</td><td>bits/s</td><td>kbits/sol</td><td>Power(mW)</td><td>Energy/sol(mWh)</td></tr></table> | <table><tr><td>Nominal (1sps during 5 min each hour)</td><td>112</td><td>806.4</td><td>0.25</td><td>0.5</td></tr><tr><td>In-flight calibration (1sps during 15 min each week)</td><td>112</td><td>14.4</td><td>500</td><td>17.8</td></tr><tr><td>Total</td><td>-</td><td>820.8</td><td>-</td><td>18.3</td></tr></table> |
13680045a5032785b0169e9636b906e5814e439a109b2c3ae66502f6221aa1a4.png | simple | <table><tr><td>Surgery Type (# of Patients) Ref.</td><td>Prognostic Value (Y/N/Insignificant)</td><td>Remarks</td></tr><tr><td>General/vascular surgery (143)39</td><td>Insignificant</td><td>Suggested conducting randomized control trial</td></tr><tr><td>Spine (268)40</td><td>Yes</td><td></td></tr><tr><td>General orthope... | <table><tr><td>Surgery Type (# of Patients) Ref.</td><td>Prognostic Value (Y/N/Insignificant)</td><td>Remarks</td></tr><tr><td>General/vascular surgery (143)39</td><td>Insignificant</td><td>Suggested conducting randomized control trial</td></tr><tr><td>Spine (268)40</td><td>Yes</td><td></td></tr><tr><td>General orthope... | <table><tr><td>Surgery Type (# of Patients) Ref.</td><td>Prognostic Value (Y/N/Insignificant)</td><td>Remarks</td></tr><tr><td></td><td>o</td><td>AS did not predict 30-day major complications after general orthopedic surgery</td></tr><tr><td>Radical cystectomy (155)42</td><td>Yes</td><td></td></tr><tr><td>General surge... |
3653099e8b384fb9e2509599c2ea32ba36907ad39ecf532b7858b179efe13217.png | complex | <table><tr><td></td><td colspan="4">No. (%) of participants from</td></tr><tr><td></td><td>Eastern Croatia</td><td>Central Croatia</td><td>Southern Croatia</td><td>Croatia</td></tr><tr><td>pH≥7.3</td><td>75 (64.1)</td><td>144 (58.3)</td><td>167 (68.7)</td><td>386 (63.6)</td></tr><tr><td>pH<7.3</td><td>42 (35.9... | <table><tr><td></td><td colspan="2">No. (%) of participants from</td></tr><tr><td></td><td>Eastern Croatia</td><td>Central Croatia</td></tr><tr><td>pH≥7.3</td><td>75 (64.1)</td><td>144 (58.3)</td></tr><tr><td>pH<7.3</td><td>42 (35.9)</td><td>103 (41.7)</td></tr><tr><td>All</td><td>117 (19.3)</td><td>247 (40.7)</td></tr... | <table><tr><td colspan="2">No. (%) of participants from</td></tr><tr><td>Southern Croatia</td><td>Croatia</td></tr><tr><td>167 (68.7)</td><td>386 (63.6)</td></tr><tr><td>76 (31.3)</td><td>221 (36.4)</td></tr><tr><td>243 (40.0)</td><td>607 (100.0)</td></tr></table> |
0c4169dbb9ba10359efbed947e1412672f459abbbe61e509da474191fe9816dc.png | simple | <table><tr><td>Asset index items</td><td>Scoring factors</td><td>% of distribution in the sample</td><td>Most poor (%)</td><td>Least poor (%)</td></tr><tr><td>Refrigerator</td><td>0.382</td><td>48.4</td><td>0</td><td>100</td></tr><tr><td>Radio</td><td>0.231</td><td>65.8</td><td>41.1</td><td>91</td></tr><tr><td>Televisi... | <table><tr><td>Asset index items</td><td>Scoring factors</td><td>% of distribution in the sample</td><td>Most poor (%)</td><td>Least poor (%)</td></tr><tr><td>Refrigerator</td><td>0.382</td><td>48.4</td><td>0</td><td>100</td></tr><tr><td>Radio</td><td>0.231</td><td>65.8</td><td>41.1</td><td>91</td></tr></table> | <table><tr><td>Asset index items</td><td>Scoring factors</td><td>% of distribution in the sample</td><td>Most poor (%)</td><td>Least poor (%)</td></tr><tr><td>Television</td><td>0.368</td><td>47.5</td><td>0</td><td>40</td></tr><tr><td>Stove</td><td>0.357</td><td>59.2</td><td>0</td><td>98</td></tr><tr><td>Phone</td><td>... |
30c9a388cfa6785fab079fb8d2fbff68b4de43aad1efbf47b5f1ae94394eb70b.png | simple | <table><tr><td>Molecular function term</td><td>% Coverage</td><td>p-value</td><td>FDR (%)</td></tr><tr><td>catalytic activity</td><td>43</td><td>1.32E-04</td><td>0.22</td></tr><tr><td>nucleotide binding</td><td>14</td><td>1.27E-05</td><td>0.02</td></tr><tr><td>purine nucleotide binding</td><td>13</td><td>4.74E-05</td><... | <table><tr><td>Molecular function term</td><td>% Coverage</td><td>p-value</td><td>FDR (%)</td></tr><tr><td>catalytic activity</td><td>43</td><td>1.32E-04</td><td>0.22</td></tr><tr><td>nucleotide binding</td><td>14</td><td>1.27E-05</td><td>0.02</td></tr><tr><td>purine nucleotide binding</td><td>13</td><td>4.74E-05</td><... | <table><tr><td>oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor</td><td>3</td><td>1.10E-04</td><td>0.19</td></tr><tr><td>translation factor activity, nucleic acid</td><td>3</td><td>2.14E-07</td><td>3.62E-04</td></tr><tr><td>GTPase activity</td><td>2</td><td>2.39E-03</td><td>3.98</td... |
fd17cdd862ff927c3061c5db9b7763178c983eb07325437a76349f350f288227.png | complex | <table><tr><td></td><td>No. of pts.</td><td>Spearmen-Rho</td><td>p-value</td></tr><tr><td>Quality of life</td><td></td><td></td><td></td></tr><tr><td>Health status</td><td>111</td><td>0.882</td><td>0.000</td></tr><tr><td>ICIQ (1)</td><td>111</td><td>−0.211</td><td>0.027</td></tr><tr><td>IPSS (2)</td><td>104</td><... | <table><tr><td></td><td>No. of pts.</td><td>Spearmen-Rho</td><td>p-value</td></tr><tr><td>Quality of life</td><td></td><td></td><td></td></tr><tr><td>Health status</td><td>111</td><td>0.882</td><td>0.000</td></tr><tr><td>ICIQ (1)</td><td>111</td><td>−0.211</td><td>0.027</td></tr><tr><td>IPSS (2)</td><td>104</td><td>−0.... | <table><tr><td></td><td>No. of pts.</td><td>Spearmen-Rho</td><td>p-value</td></tr><tr><td>t survey</td><td></td><td></td><td></td></tr><tr><td>IPSS (preimplant)</td><td>103</td><td>0.287</td><td>0.003</td></tr><tr><td colspan="2">Seed dislocation/loss</td><td></td><td></td></tr><tr><td>V100 (4)</td><td>163</td><td>−0.2... |
37296058f9af828815c7198d93413596b70c017dfb5db2dd0ad4c81701021b5d.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2">INTAKE24 Geometric Mean</td><td rowspan="2">Interview Geometric Mean</td><td rowspan="2">Ratio of Geometric Mean</td><td colspan="2">Limits of Agreement</td></tr><tr><td>Lower</td><td>Upper</td></tr><tr><td>Energy (kJ)</td><td>6681.7</td><td>6823.9</td><td>0.97</td><td>0.... | <table><tr><td></td><td>INTAKE24 Geometric Mean</td><td>Interview Geometric Mean</td><td>Ratio of Geometric Mean</td><td colspan="2">Limits of Agreement</td></tr></table> | <table><tr><td></td><td>INTAKE24 Geometric Mean</td><td>Interview Geometric Mean</td><td>Ratio of Geometric Mean</td><td>Lower</td><td>Upper</td></tr><tr><td>Energy (kJ)</td><td>6681.7</td><td>6823.9</td><td>0.97</td><td>0.52</td><td>1.82</td></tr><tr><td>Carbohydrate (g)</td><td>234.2</td><td>236.0</td><td>0.99</td><t... |
effc7b1a24c145d13d64b7c2afed15bc2648daf2e8a0da9c43b1952bb44d0677.png | complex | <table><tr><td rowspan="2">Wheat in OSR (in 2000)</td><td rowspan="2">Infectivity of Soil (% roots)a</td><td colspan="2">Take-All in Spring</td><td colspan="2">Take-All in Summer</td><td rowspan="2">Take-All Index (0–100)</td><td rowspan="2">Grain Yield (t ha<sup>−1</sup>)</td></tr><tr><td>Total(% plants)</... | <table><tr><td rowspan="2">Wheat in OSR (in 2000)</td><td rowspan="2">Infectivity of Soil (% roots)a</td><td colspan="2">Take-All in Spring</td><td colspan="2">Take-All in Summer</td><td rowspan="2">Take-All Index (0–100)</td><td rowspan="2">Grain Yield (t ha−1)</td></tr><tr><td>Total(% plants)</td><td>No. Roots(plant−... | <table><tr><td>Destroyed late</td><td>−2.03 (1.2)</td><td>−1.61 (3.4)</td><td>0.06</td><td>−1.81 (2.1)</td><td>−2.45 (0.2)</td><td>0.7</td><td>8.31</td></tr><tr><td>Not destroyed</td><td>−1.92 (1.6)</td><td>−1.12 (9.1)</td><td>0.25</td><td>−1.37 (5.5)</td><td>−2.09 (1.0)</td><td>3.5</td><td>8.46</td></tr><tr><td>SED (2... |
368750988376f353fcb7dff27d89427b39011ce0e7238af916804bb397854163.png | simple | <table><tr><td>Organism</td><td>Release version</td><td>Coverage depth</td><td>Genome size (Mbp)</td><td>Scaffolds numbers</td><td>EST Size (Mbp)</td><td>EST numbers</td></tr><tr><td>Aq</td><td>v1.0</td><td>~8X</td><td>143</td><td>3,579</td><td>42</td><td>63,542</td></tr><tr><td>Ta</td><td>v1.0</td><td>~8.1X</td><td>10... | <table><tr><td>Organism</td><td>Release version</td><td>Coverage depth</td><td>Genome size (Mbp)</td><td>Scaffolds numbers</td><td>EST Size (Mbp)</td><td>EST numbers</td></tr><tr><td>Aq</td><td>v1.0</td><td>~8X</td><td>143</td><td>3,579</td><td>42</td><td>63,542</td></tr><tr><td>Ta</td><td>v1.0</td><td>~8.1X</td><td>10... | <table><tr><td>Organism</td><td>Release version</td><td>Coverage depth</td><td>Genome size (Mbp)</td><td>Scaffolds numbers</td><td>EST Size (Mbp)</td><td>EST numbers</td></tr><tr><td>Nv</td><td>v1.0</td><td>~7.8X</td><td>356</td><td>10,804</td><td>133</td><td>163,314</td></tr><tr><td>Ct</td><td>v1.0</td><td>~7.9X</td><... |
fe4a173d6b62fdc1db01f7d35b8e671e7dac9b0ee373a2334cfcbccd43f726ce.png | simple | <table><tr><td>System</td><td>Manifestation</td></tr><tr><td>Digestive system</td><td>Burning throat, nausea, vomiting, abdominal pain, abdominal distension</td></tr><tr><td>Nervous system</td><td>Dizziness, vertigo, dysarthria, dysphagia, blurred vision, diplopia, drooping eyelids, mydriasis, miosis, absence of pupill... | <table><tr><td>System</td><td>Manifestation</td></tr><tr><td>Digestive system</td><td>Burning throat, nausea, vomiting, abdominal pain, abdominal distension</td></tr><tr><td></td><td>Dizziness, vertigo, dysarthria, dysphagia, blurred vision, diplopia, drooping eyelids, mydriasis, miosis, absence of pupillary light refl... | <table><tr><td>System</td><td>Manifestation</td></tr><tr><td>Nervous system</td><td>ia, fatigue, convulsion, numbness, restlessness, loss of consciousness</td></tr><tr><td>Respiratory system</td><td>Chest tightness, tachypnea, bradypnea, shortness of breath, irregular breathing, respiratory arrest, cyanosis</td></tr><t... |
865951c8ffd2a24a4ad00a307111864ed56a0471afb76906390cb77f86055a0a.png | complex | <table><tr><td>Entry Plasmids<sup>a</sup></td><td colspan="2">Applications</td></tr><tr><td colspan="2">pL1R5-BGHpA-empty</td><td>1. The TALEN Entry plasmid pairs can be used for </td></tr><tr><td colspan="2">pL1R5-CAG-EGFP-T2A-TALEN-NN-BGHpA</td><td> TALEN functional tests.</td></tr><tr><td colspan="2">pL1R5-CAG-EGFP-... | <table><tr><td>Entry Plasmidsa</td><td>Applications</td></tr><tr><td colspan="2">pL1R5-BGHpA-empty</td></tr><tr><td colspan="2">pL1R5-CAG-EGFP-T2A-TALEN-NN-BGHpA</td></tr><tr><td colspan="2">pL1R5-CAG-EGFP-T2A-TALEN-NI-BGHpA</td></tr><tr><td colspan="2">pL1R5-CAG-EGFP-T2A-TALEN-NG-BGHpA</td></tr><tr><td colspan="2">pL1... | <table><tr><td>Applications</td></tr><tr><td>1. The TALEN Entry plasmid pairs can be used for</td></tr><tr><td>TALEN functional tests.</td></tr><tr><td>2. The TALEN Entry plasmids contain EGFP or</td></tr><tr><td>mCherry reporters, which can be used for</td></tr><tr><td>monitoring transfection efficiency and cell sorti... |
47a41b043459c22d7f5f131dc93008d7c2225842cf8ecf8924864a5c2247ac2b.png | complex | <table><tr><td>Gene</td><td>Primers</td><td>Sequence</td></tr><tr><td rowspan="2"><i>PRP8</i></td><td>Forward</td><td>TCATGGCTGCGTCTGAAGTA</td></tr><tr><td>Reverse</td><td>GGCTCAAACCCTTCCGATAG</td></tr><tr><td rowspan="2"><i>MET18</i></td><td>Forward</td><td>TGCTGGAAGTTGTCGTTGC</td></tr><tr><td>Reverse</td><td>TCGTTTTT... | <table><tr><td>Gene</td><td>Primers</td><td>Sequence</td></tr><tr><td rowspan="2">PRP8</td><td>Forward</td><td>TCATGGCTGCGTCTGAAGTA</td></tr><tr><td>Reverse</td><td>GGCTCAAACCCTTCCGATAG</td></tr><tr><td rowspan="2">MET18</td><td>Forward</td><td>TGCTGGAAGTTGTCGTTGC</td></tr><tr><td>Reverse</td><td>TCGTTTTTGGAGAGGTGGTC</... | <table><tr><td>CTA1</td><td>Reverse</td><td>TTACCCAAAACGCGGTAGAG</td></tr></table> |
e006f5b82dc53de5708b99d445ff98e44016afc8f96a096dd109b610be9beb51.png | simple | <table><tr><td>Species</td><td># of Strains</td><td>Genome size (Mb)</td><td>GC content (%)</td></tr><tr><td>Fungi (Kingdom)</td><td></td><td></td><td></td></tr><tr><td> Ascomycota (Phylum)</td><td></td><td></td><td></td></tr><tr><td>Pezizomycotina (Subphylum)</td><td></td><td></td><td></td></tr><tr><td><i>Aspergillus ... | <table><tr><td>Species</td><td># of Strains</td><td>Genome size (Mb)</td><td>GC content (%)</td></tr><tr><td>Fungi (Kingdom)</td><td></td><td></td><td></td></tr><tr><td>Ascomycota (Phylum)</td><td></td><td></td><td></td></tr><tr><td>Pezizomycotina (Subphylum)</td><td></td><td></td><td></td></tr><tr><td>Aspergillus fumi... | <table><tr><td>Saccharomycotina (Subphylum)</td><td></td><td></td><td></td></tr><tr><td>Candida albicans</td><td>2</td><td>14.4 ± 0.1</td><td>33.462 ± 0.010</td></tr><tr><td>Saccharomyces cerevisiae</td><td>3</td><td>11.9 ± 0.3</td><td>38.252 ± 0.090</td></tr><tr><td>Saccharomyces bayanus</td><td>2</td><td>11.7 ± 0.3</... |
4410a7f69337c6b43d291d33b27ba0ca8cf9add20b1e2eb1e62a33a116357573.png | simple | <table><tr><td>Complication</td><td>Evisceration Incidence/%</td><td>Enucleation Incidence/%</td><td><i>P</i> value (Fisher’s exact test)</td></tr><tr><td>No complication</td><td>30/71.4</td><td>16/61.5</td><td>0.43</td></tr><tr><td>Wound dehiscence</td><td>4/9.5</td><td>3/11.5</td><td>1.00</td></tr><tr><td>Impla... | <table><tr><td>Complication</td><td>Evisceration Incidence/%</td></tr><tr><td>No complication</td><td>30/71.4</td></tr><tr><td>Wound dehiscence</td><td>4/9.5</td></tr><tr><td>Implant exposure</td><td>2/4.8</td></tr><tr><td>Implant extrusion</td><td>1/2.4</td></tr><tr><td>Implant migration</td><td>0/0</td></tr><tr><td>I... | <table><tr><td>Enucleation Incidence/%</td><td>P value (Fisher’s exact test)</td></tr><tr><td>16/61.5</td><td>0.43</td></tr><tr><td>3/11.5</td><td>1.00</td></tr><tr><td>1/3.8</td><td>1.00</td></tr><tr><td>2/7.7</td><td>0.55</td></tr><tr><td>1/3.8</td><td>0.38</td></tr><tr><td>1/3.8</td><td>1.00</td></tr><tr><td>2/7.7</... |
6ba7f519becd9d32ab88de11e4961610c2474ce4ed6b4d91ae42948abb082534.png | complex | <table><tr><td colspan="2"></td><td colspan="6">Female</td></tr><tr><td rowspan="2"></td><td>Genotype</td><td colspan="3">wt/wt</td><td colspan="3">KO/KO</td></tr><tr><td>Treatment</td><td>Vehicle</td><td>AngII</td><td>Δ</td><td>Vehicle</td><td>AngII</td><td>Δ</td></tr><tr><td rowspan="5">Aorta</td><td>HR (bp... | <table><tr><td colspan="2"></td><td colspan="6">Female</td></tr><tr><td rowspan="2"></td><td>Genotype</td><td colspan="3">wt/wt</td><td colspan="3">KO/KO</td></tr><tr><td>Treatment</td><td>Vehicle</td><td>AngII</td><td>Δ</td><td>Vehicle</td><td>AngII</td><td>Δ</td></tr><tr><td rowspan="5">Aorta</td><td>HR (bpm)</td><td... | <table><tr><td rowspan="4">Morphometry</td><td>HW:TL (mg/mm)</td><td>6.5 ± 0.1</td><td>8.1 ± 0.2*</td><td>1.6</td><td>6.8 ± 0.1</td><td>8.2 ± 0.2*</td><td>1.4</td></tr><tr><td>LVW:TL (mg/mm)</td><td>4.6 ± 0.1</td><td>6.0 ± 0.2*</td><td>1.4</td><td>4.9 ± 0.1</td><td>6.2 ± 0.1*</td><td>1.3</td></tr><tr><td>RVW:TL (mg/mm)... |
842a1a29fcbd8f1ebae85412e9f65be315a48f4771cdb7313ddc58a42eee5719.png | simple | <table><tr><td>Epigenetic Process</td><td>Target</td><td>Function</td></tr><tr><td>DNA Methylation</td><td>DNA in cell or viral epigenome</td><td>Typically silence genes</td></tr><tr><td>Nucleosome Location</td><td>Cellular and Viral Chromatin</td><td>Nucleosome position controls access to DNA sequences</td></tr><tr><t... | <table><tr><td>Epigenetic Process</td><td>Target</td></tr><tr><td>DNA Methylation</td><td>DNA in cell or viral epigenome</td></tr><tr><td>Nucleosome Location</td><td>Cellular and Viral Chromatin</td></tr><tr><td>Histone Modification</td><td>Cellular and Viral Chromatin</td></tr><tr><td>Histone Variants</td><td>Cellular... | <table><tr><td>Function</td></tr><tr><td>Typically silence genes</td></tr><tr><td>Nucleosome position controls access to DNA sequences</td></tr><tr><td>Histone acetylation and methylation on H3K4/H3K36 association with activation of transcription, methylation on H3K9 and H3K27 is associated with repression, methylation... |
921526c2d697de2ea9fb0498cb835e2b73583cfcc390538a38962556d02cdc54.png | complex | <table><tr><td>Chromosomes</td><td colspan="4">% Aneuploidy (loss, gain)</td></tr><tr><td></td><td>Healthy brain</td><td>AT</td><td>AD</td><td>Schizo</td></tr><tr><td>1</td><td>0.5 (0.3, 0.2)</td><td>2.8 (1.7, 1.1)</td><td>0.7 (0.3, 0.4)</td><td>1.8 (0.9, 0.9)</td></tr><tr><td>7</td><td>0.7 (0.3, 0.4)</td><td>1.5 (0.6,... | <table><tr><td>Chromosomes</td><td colspan="4">% Aneuploidy (loss, gain)</td></tr><tr><td></td><td>Healthy bra</td><td>AT</td><td></td><td>S</td></tr></table> | <table><tr><td></td><td>in</td><td></td><td>AD</td><td>chizo</td></tr><tr><td>1</td><td>0.5 (0.3, 0.2)</td><td>2.8 (1.7, 1.1)</td><td>0.7 (0.3, 0.4)</td><td>1.8 (0.9, 0.9)</td></tr><tr><td>7</td><td>0.7 (0.3, 0.4)</td><td>1.5 (0.6, 0.8)</td><td>NA</td><td>NA</td></tr><tr><td>8</td><td>1.0 (0.3, 0.7)</td><td>2.8 (0.8, 2... |
1744ba411261a53e6264f908ba6e1d79607420c156196bb4239c7a85eb1500a7.png | simple | <table><tr><td>Different techniques</td><td>NESP for single pulse</td><td>Ave. NESP for orthogonal pulses</td></tr><tr><td>Seventh derivative Gaussian pulse [35]</td><td>46%</td><td>-</td></tr><tr><td>Hermite Gaussian Functions [20]</td><td>65%</td><td>65%</td></tr><tr><td>PM algorithm [10]</td><td>72.41%</td><td>-</td... | <table><tr><td>Different techniques</td><td>NESP for single pulse</td></tr><tr><td>Seventh derivative Gaussian pulse [35]</td><td>46%</td></tr><tr><td>Hermite Gaussian Functions [20]</td><td>65%</td></tr><tr><td>PM algorithm [10]</td><td>72.41%</td></tr><tr><td>SOCP based FIR filter [14]</td><td>79%</td></tr><tr><td>SO... | <table><tr><td>Ave. NESP for orthogonal pulses</td></tr><tr><td>-</td></tr><tr><td>65%</td></tr><tr><td>-</td></tr><tr><td>77.5%</td></tr><tr><td>59.26%</td></tr><tr><td>98.7%</td></tr></table> |
02ddf452dfb66d38d1258561b3121889f875d567815fb0c80fa9cae7e443475f.png | complex | <table><tr><td> </td><td colspan="3">KPs</td><td colspan="3">Aqueous cells</td><td colspan="3">Aqueous flare</td><td colspan="3">Vitreous cells</td></tr><tr><td>Patient number</td><td>0</td><td>1</td><td>3</td><td>0</td><td>1</td><td>3</td><td>0</td><td>1</td><td>3</td><td>0</td><td>1</td><td>3</td></tr><tr><td>1</td><... | <table><tr><td></td><td colspan="3">KPs</td><td colspan="3">Aqueous cells</td><td colspan="3">Aqueous flare</td><td colspan="3">Vitreous cells</td></tr><tr><td>Pa</td><td></td><td></td><td>3</td><td></td><td></td><td>3</td><td>0</td><td>1</td><td>3</td><td>0</td><td></td><td></td></tr></table> | <table><tr><td>tient number</td><td>0</td><td>1</td><td></td><td>0</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>3</td></tr><tr><td>1</td><td>+++</td><td>++</td><td>±</td><td>+++</td><td>++</td><td>+</td><td>+++</td><td>++</td><td>+</td><td>++</td><td>+</td><td>±</td></tr><tr><td>2</td><td>++... |
17bdc360e88ce805de439c15bab48b5fb465698327ae9f1268302a553627d864.png | simple | <table><tr><td>Placing State</td><td>Other Experiment Settings</td></tr><tr><td>Static</td><td>Running the whole ARS</td></tr><tr><td>Static</td><td>Only running Sensors</td></tr><tr><td>Static</td><td>Running the ARS without activity recognition and result processing</td></tr><tr><td>Static</td><td>Running the ARS wit... | <table><tr><td>Placing State</td><td>Other Experiment Settings</td></tr></table> | <table><tr><td>Static</td><td>Running the whole ARS</td></tr><tr><td>Static</td><td>Only running Sensors</td></tr><tr><td>Static</td><td>Running the ARS without activity recognition and result processing</td></tr><tr><td>Static</td><td>Running the ARS without result processing</td></tr><tr><td>Static</td><td>The phone ... |
b7e87d60cb541ef7ae75641dbb3b0d092af0c4c98f535ab474889aba20070123.png | complex | <table><tr><td rowspan="2"></td><td>Lower UTI</td><td>Control</td><td rowspan="2">P value</td></tr><tr><td>(n = 13)</td><td>(n = 24)</td></tr><tr><td rowspan="2">Leucocyte count (G/l)</td><td>8.6 ± 3.3</td><td>6.43 ± 2.1</td><td rowspan="2">NS</td></tr><tr><td>[7.4 (3.4)]</td><td>[5.6 (3.3)]</td></tr><tr><td ... | <table><tr><td rowspan="2"></td><td>Lower UTI</td><td>Control</td><td rowspan="2">P value</td></tr><tr><td>(n = 13)</td><td>(n = 24)</td></tr><tr><td rowspan="2">Leucocyte count (G/l)</td><td>8.6 ± 3.3</td><td>6.43 ± 2.1</td><td rowspan="2">NS</td></tr><tr><td>[7.4 (3.4)]</td><td>[5.6 (3.3)]</td></tr><tr><td rowspan="2... | <table><tr><td rowspan="2"></td><td>Lower UTI</td><td>Control</td><td rowspan="2">P value</td></tr><tr><td>(n = 13)</td><td>(n = 24)</td></tr><tr><td rowspan="2">PCT (ng/ml)</td><td>0.05 ± 0</td><td>0.06 ± 0.02</td><td rowspan="2">NS</td></tr><tr><td>[0.05 (0)]</td><td>[0.05 (0)]</td></tr><tr><td rowspan="2">IL −6 (pg/... |
86e6d91cbfded9d9436718e97ce3eeddc6a11eeee86728808be7f011a8343d69.png | complex | <table><tr><td>Method</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td></tr><tr><td colspan="10">A.RANKING ORDER UNDER ALL STRESS(BETTER-GOOD-AVERAGE)</td></tr><tr><td> geNorm</td><td>MAP/UBC</td><td></td><td>FHP</td><td>EF 1-α</td><td>CGS1</td><td>PPK</td><td>ATPase</t... | <table><tr><td>Method</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td></tr><tr><td colspan="10">A.RANKING ORDER UNDER ALL STRESS(BETTER-GOOD-AVERAGE)</td></tr><tr><td>geNorm</td><td>MAP/UBC</td><td></td><td>FHP</td><td>EF 1-α</td><td>CGS1</td><td>PPK</td><td>ATPase</td><td>... | <table><tr><td>Comprehensive ranking</td><td>CGS1</td><td>UBC</td><td>FHP</td><td>PPK</td><td>MAP</td><td>EF 1-α</td><td>eif4A</td><td>DPE2</td><td>ATPase</td></tr><tr><td colspan="10">C.RANKING ORDER UNDER TEMPERATURE STRESS (BETTER-GOOD-AVERAGE)</td></tr><tr><td>geNorm</td><td>MAP/ATPase</td><td></td><td>EF 1-α</td><... |
fac201ab137d74e2e66bb4ca21c63894f37dbe3b6919c4e32f2755b8719ce516.png | simple | <table><tr><td>System</td><td>Effect</td><td>Manifestation</td></tr><tr><td><i>Renal</i></td><td>Renal vein compression, cortical arteriolar compression</td><td>Oliguria, rising creatinine</td></tr><tr><td><i>Pulmonary</i></td><td>Upward pressure on diaphragm, decreased compliance and functional residual capacity, incr... | <table><tr><td>System</td><td>Effect</td></tr><tr><td>Renal</td><td>Renal vein compression, cortical arteriolar compression</td></tr><tr><td>Pulmonary</td><td>Upward pressure on diaphragm, decreased compliance and functional residual capacity, increased air way resistance</td></tr><tr><td>Cardiovascular</td><td>Decreas... | <table><tr><td>Manifestation</td></tr><tr><td>Oliguria, rising creatinine</td></tr><tr><td>Hypoxia, hypercarbia, elevated airway pressure, decreased tidal volume</td></tr><tr><td>Decreased cardiac output</td></tr><tr><td>Elevated Intra Cranial Pressure</td></tr><tr><td>Metabolic acidosis, bowel ischemia</td></tr></tabl... |
fa3290320e813dc4178a8500f8f94a56429600a3c3510066285ce69a5a123e47.png | simple | <table><tr><td></td><td>Ever Delirium (n = 125)</td><td>Never Delirium (n = 135)</td><td>p-value</td></tr><tr><td>Characteristic</td><td></td><td></td><td></td></tr><tr><td> Mean age (± 1 SD; years)</td><td>56 (± 18)</td><td>49 (± 17)</td><td>0.002</td></tr><tr><td> Male</td><td>62 (50%)</td><td>67 (50%)... | <table><tr><td></td><td>Ever Delirium (n = 125)</td><td>Never Delirium (n = 135)</td><td>p-value</td></tr><tr><td>Characteristic</td><td></td><td></td><td></td></tr></table> | <table><tr><td></td><td>Ever Delirium (n = 125)</td><td>Never Delirium (n = 135)</td><td>p-value</td></tr><tr><td>Mean age (± 1 SD; years)</td><td>56 (± 18)</td><td>49 (± 17)</td><td>0.002</td></tr><tr><td>Male</td><td>62 (50%)</td><td>67 (50%)</td><td>1.0</td></tr><tr><td>No. of Caucasians</td><td>99 (79%)</td><td>115... |
725f720b63be604ffa8cf2e937c05e183ecf39af4db187d9d6aa571998b21e54.png | simple | <table><tr><td></td><td><i>Function-based screening</i></td><td><i>Sequence-based screening</i></td><td><i>SIGEX</i></td></tr><tr><td>Screening principle</td><td>• Detecting changes by enzymatic reactions (e.g. halo formation around the colonies)</td><td>• PCR or Southern hybridization based on the DNA sequ... | <table><tr><td></td><td>Function-based screening</td><td>Sequence-based screening</td><td>SIGEX</td></tr><tr><td>Screening principle</td><td>• Detecting changes by enzymatic reactions (e.g. halo formation around the colonies)</td><td>• PCR or Southern hybridization based on the DNA sequence consensus</td><td>• Trapping... | <table><tr><td></td><td>Function-based screening</td><td>Sequence-based screening</td><td>SIGEX</td></tr><tr><td>Examples</td><td>antibiotics [9, 19-22], genes involved antibiotic resistance [9, 23, 24], agarases [15], amidases [13], amylases [15, 21, 25, 26], esterase/lipases [8, 15, 21, 27, 28], xylanases [29], 4-hyd... |
7b3b138288508e9dbc62b2cae0675b7a2e0e13fd0184d78fff5b40d57d10bac1.png | simple | <table><tr><td>Instrument</td><td>FAST Year 1</td><td>GDS Year 1</td><td>CDR-GS Year 1</td></tr><tr><td>AQ Year 1</td><td>0.84</td><td>0.78</td><td>0.74</td></tr><tr><td>FAQ Year 1</td><td>0.83</td><td>0.77</td><td>0.75</td></tr><tr><td>MMSE Year 1</td><td>-0.59</td><td>-0.64</td><td>-0.65</td></tr></table> | <table><tr><td>Instrument</td><td>FAST Year 1</td><td>GDS Year 1</td></tr><tr><td>AQ Year 1</td><td>0.84</td><td>0.78</td></tr><tr><td>FAQ Year 1</td><td>0.83</td><td>0.77</td></tr><tr><td>MMSE Year 1</td><td>-0.59</td><td>-0.64</td></tr></table> | <table><tr><td>CDR-GS Year 1</td></tr><tr><td>0.74</td></tr><tr><td>0.75</td></tr><tr><td>-0.65</td></tr></table> |
cc5f0a891f5f8665bbf3289facddce86214205330b1e7e2b1db30f3ba356ae47.png | complex | <table><tr><td>Group</td><td>AGEs</td><td><i>p</i> Value</td><td>sRAGE</td><td><i>p</i> Value</td></tr><tr><td rowspan="2">Control group</td><td>16.89 ± 2.98</td><td>0.001</td><td>3.01 ± 1.53</td><td>0.0001</td></tr><tr><td>16.82 (11.1)</td><td></td><td>3 (3.8)</td><td></td></tr><tr><td>All Hemodialysis group... | <table><tr><td>Group</td><td>AGEs</td><td>p Value</td><td>sRAGE</td><td>p Value</td></tr><tr><td rowspan="2">Control group</td><td>16.89 ± 2.98</td><td>0.001</td><td>3.01 ± 1.53</td><td>0.0001</td></tr><tr><td>16.82 (11.1)</td><td></td><td>3 (3.8)</td><td></td></tr><tr><td>All Hemodialysis groups</td><td>18.92 ± 4.1517... | <table><tr><td>Group</td><td>AGEs</td><td>p Value</td><td>sRAGE</td><td>p Value</td></tr><tr><td>)</td><td> 3.3819.6 (9.6)</td><td></td><td>.83)</td><td></td></tr><tr><td>DM−CVD− (4)</td><td>18.13 ± 3.9516.98 (17.1)</td><td></td><td>7.39 ± 2.818.3 (9.6)</td><td></td></tr></table> |
4ba434bd3142dc1d62ae8361c775eae39fb898edc583d43c99379abf56f98adc.png | simple | <table><tr><td></td><td>odds ratio</td><td>95% CI</td><td><i>p</i>-value</td></tr><tr><td>Age, years (mean ± SD)</td><td>1.01</td><td>0.88–1.15</td><td>0.920</td></tr><tr><td>Education, years (mean ± SD)</td><td>1.02</td><td>0.88–1.21</td><td>0.778</td></tr><tr><td>Gender, female (%)</td><td>3.33<... | <table><tr><td></td><td>odds ratio</td><td>95% CI</td><td>p-value</td></tr><tr><td>Age, years (mean ± SD)</td><td>1.01</td><td>0.88–1.15</td><td>0.920</td></tr><tr><td>Education, years (mean ± SD)</td><td>1.02</td><td>0.88–1.21</td><td>0.778</td></tr></table> | <table><tr><td>Gender, female (%)</td><td>3.33</td><td>0.68–18.62</td><td>0.146</td></tr><tr><td>1st CDR-SB</td><td>0.90</td><td>0.63–1.28</td><td>0.573</td></tr><tr><td>1st MMSE</td><td>1.00</td><td>0.82–1.22</td><td>0.962</td></tr><tr><td>Cilostazol use</td><td>0.51</td><td>0.12–1.99</td><td>0.331</td></tr><tr><td>Ap... |
40b5d48412db4e4f8c7d12469477744ef1dc1297f5e7df4855230699d560c8ba.png | complex | <table><tr><td rowspan="3">Items</td><td colspan="3">single</td><td colspan="3">multiple</td></tr><tr><td>OR</td><td>95% CI</td><td><i>P</i></td><td>OR</td><td>95% CI</td><td><i>P</i></td></tr><tr><td>Sing songs with your child</td><td>1.82<sup>a</sup></td><td>1.10–3.01</td><td>0.0204</td><td>1.71<sup>a</sup></td... | <table><tr><td rowspan="3">Items</td><td colspan="3">single</td><td colspan="2">multiple</td></tr><tr><td>OR</td><td>95% CI</td><td>P</td><td>OR</td><td>95% CI</td></tr><tr><td colspan="5"></td></tr><tr><td>Sing songs with your child</td><td>1.82a</td><td>1.10–3.01</td><td>0.0204</td><td>1.71a</td><td>1.01–2.89</td></t... | <table><tr><td>multiple</td></tr><tr><td>P</td></tr><tr><td></td></tr><tr><td>0.0475</td></tr><tr><td>0.0416</td></tr><tr><td>0.2536</td></tr><tr><td>0.8735</td></tr><tr><td>0.3631</td></tr><tr><td>0.4560</td></tr><tr><td>0.5340</td></tr><tr><td>0.4093</td></tr><tr><td>0.8496</td></tr><tr><td>0.1239</td></tr><tr><td>0.... |
986b9332db46d402c9e92493a900083f9721c7c62854046098086884b9452d43.png | simple | <table><tr><td>Pathology</td><td>Young</td><td>AdV</td><td>1 mo post DSB</td><td>2 mo post DSB</td><td>Old</td></tr><tr><td>Karyomegaly</td><td>1.62±0.38</td><td>2.27±0.14</td><td>3.00±0*</td><td>2.25±0.25</td><td>4.00±0**</td></tr><tr><td>Intranuclear inclusions</td><td>0±0</td><td>0.09&#... | <table><tr><td>Pathology</td><td>Young</td><td>AdV</td><td>1 mo post DSB</td><td>2 mo post DSB</td><td>Old</td></tr><tr><td>Karyomegaly</td><td>1.62±0.38</td><td>2.27±0.14</td><td>3.00±0*</td><td>2.25±0.25</td><td>4.00±0**</td></tr><tr><td>Intranucle</td><td>0</td><td>0.09±0.</td><td>0.</td><td>0.38</td><td>3.00</td></... | <table><tr><td>Pathology</td><td>Young</td><td>AdV</td><td>1 mo post DSB</td><td>2 mo post DSB</td><td>Old</td></tr><tr><td>ar inclusions</td><td>±0</td><td>10</td><td>38±0.13#</td><td>±0.13#</td><td>±0**</td></tr><tr><td>Lobular infiltrates</td><td>0.38±0.24</td><td>0.81±0.26</td><td>1.63±0.13*</td><td>1.38±0.24</td><... |
1988c9445646e6f45bf9c86abd5e9a520dda04cbc0c337f9618c6741559696bc.png | simple | <table><tr><td>Program</td><td>50</td><td>150</td><td>250</td></tr><tr><td>B-TBLASTN</td><td>0.458 ± 0.004</td><td>0.478 ± 0.002</td><td>0.484 ± 0.001</td></tr><tr><td>S-TBLASTN</td><td>0.454 ± 0.004</td><td>0.471 ± 0.002</td><td>0.478 ± 0.001</td></tr><tr><td>C-TBLASTN</td><td>0.455 ±... | <table><tr><td>Program</td></tr><tr><td>B-TBLASTN</td></tr><tr><td>S-TBLASTN</td></tr><tr><td>C-TBLASTN</td></tr></table> | <table><tr><td>50</td><td>150</td><td>250</td></tr><tr><td>0.458 ± 0.004</td><td>0.478 ± 0.002</td><td>0.484 ± 0.001</td></tr><tr><td>0.454 ± 0.004</td><td>0.471 ± 0.002</td><td>0.478 ± 0.001</td></tr><tr><td>0.455 ± 0.004</td><td>0.474 ± 0.002</td><td>0.481 ± 0.001</td></tr></table> |
f10037ed118c15afdfacb9c72cd17f5b192ae71a43ddddfae6366f253af9c157.png | simple | <table><tr><td>Classifier</td><td>Accuracy (%)</td><td>Recall rate (%)</td><td>F1 measure</td><td>Time (s)</td></tr><tr><td>EEG</td><td>94.2</td><td>92.8</td><td>93.7</td><td>0.01</td></tr><tr><td>Skeleton</td><td>93.8</td><td>93.4</td><td>93.8</td><td>0.01</td></tr><tr><td>Skeleton-EEG</td><td>94.7</td><td>94.6</td><t... | <table><tr><td>Classifier</td><td>Accuracy (%)</td><td>Recall rate (%)</td><td>F1 measure</td><td>Time (s)</td></tr><tr><td>EEG</td><td>94.2</td><td>92.8</td><td>93.7</td><td>0.01</td></tr><tr><td>Skeleton</td><td>93.8</td><td>93.4</td><td>93.8</td><td>0.01</td></tr></table> | <table><tr><td>Skeleton-EEG</td><td>94.7</td><td>94.6</td><td>94.2</td><td>0.01</td></tr><tr><td>Integrated</td><td>96.5</td><td>96.4</td><td>96.2</td><td>0.01</td></tr></table> |
d027f123a9098b0a9b638f69923509b060c01bab8b6d5c16de2ab300569342da.png | simple | <table><tr><td>Group</td><td>Cases, n</td><td>In-stent restenosis, n (%)</td><td>Angina, n (%)</td><td>Myocardial infarction, n (%)</td><td>Heart failure, n (%)</td><td>Revascularization (unchanged number), n (%)</td><td>All-cause mortality, n (%)</td><td>MACE events, n (%)</td><td>Medical costs, RMB</td></tr><tr><td>C... | <table><tr><td>Group</td><td>Cases, n</td><td>In-stent restenosis, n (%)</td><td>Angina, n (%)</td><td>Myocardial infarction, n (%)</td><td>Heart failure, n (%)</td><td>Revascularization (unchanged number), n (%)</td><td>All-cause mortality, n (%)</td><td>MACE events, n (%)</td><td>Medical costs, RMB</td></tr><tr><td>C... | <table><tr><td>FR</td><td>856</td><td>111 (12.9)</td><td>246 (28.7)</td><td>19 (2.2)</td><td>84 (9.8)</td><td>111 (12.9)</td><td>15 (1.8)</td><td>248 (29)</td><td>83,200</td></tr><tr><td>PR</td><td>433</td><td>63 (14.6)</td><td>191 (44.1)</td><td>12 (2.8)</td><td>93 (21.4)</td><td>98 (22.8)</td><td>17 (3.9)</td><td>290... |
b72d640426198afc796acd024515306e09523f87b7762329b8563026a0a9470d.png | complex | <table><tr><td></td><td colspan="4">Interval from calving</td></tr><tr><td></td><td>50-70</td><td>71-100</td><td>101-</td><td>Total</td></tr><tr><td>Parity</td><td></td><td></td><td></td><td></td></tr><tr><td> 0</td><td></td><td></td><td></td><td>27.3 (22)</td></tr><tr><td> 1</td><td>25.0 (8)</td><td>10.7 (28)</td><td>... | <table><tr><td></td><td colspan="2">Interval from calving</td></tr><tr><td></td><td>50-70</td><td>71-100</td></tr><tr><td>Parity</td><td></td><td></td></tr><tr><td>0</td><td></td><td></td></tr><tr><td>1</td><td>25.0 (8)</td><td>10.7 (28)</td></tr><tr><td>2-5</td><td>18.2 (11)</td><td>16.9 (59)</td></tr><tr><td>6-</td><... | <table><tr><td colspan="2">Interval from calving</td></tr><tr><td>101-</td><td>Total</td></tr><tr><td></td><td></td></tr><tr><td></td><td>27.3 (22)</td></tr><tr><td>25.0 (8)</td><td>15.9 (44)</td></tr><tr><td>25.0 (12)</td><td>18.3 (82)</td></tr><tr><td>50.0 (2)</td><td>37.5 (16)</td></tr><tr><td>27.3 (22)</td><td></td... |
5a356c8a391512de34f54f82da59d39b6d17b72513e2a45f49062aaa6aace6a2.png | simple | <table><tr><td>Probable</td></tr><tr><td>Probable CVID</td></tr><tr><td>Male or female patient who has a marked decrease of IgG (at least 2 SD below the mean for age) and a marked decrease in at least one of the isotypes IgM or IgA, and fulfils all of the following criteria:</td></tr><tr><td> ∙ Onset of immunodef... | <table><tr><td>Probable</td></tr><tr><td>Probable CVID</td></tr><tr><td>Male or female patient who has a marked decrease of IgG (at least 2 SD below the mean for age) and a marked decrease in at least one of the isotypes IgM or IgA, and fulfils all of the following criteria:</td></tr><tr><td>∙ Onset of immunodeficiency... | <table><tr><td>Probable</td></tr><tr><td>e been excluded</td></tr><tr><td>Possible CVID</td></tr><tr><td>Male or female patient who has a marked decrease (at least 2 SD below the mean for age) in at least one of the major isotypes (IgM, IgG, and IgA) and fulfils all of the following criteria:</td></tr><tr><td>1. Onset ... |
d8865e882302640e66a7ea6e30724756246dc4b7fe69bb912a1fe8b29c8bd0a1.png | simple | <table><tr><td>Affymetrix ID</td><td>FoldΔ</td><td>GenBank</td><td>Gene</td><td>Gene Description</td></tr><tr><td>1384944_at</td><td>43.3</td><td>BE116855</td><td>Bcl11b</td><td>B-cell leukemia/lymphoma 11B (predicted)</td></tr><tr><td>1370041_at</td><td>11.7</td><td>NM_053440</td><td>Stmn2</td><td>stathmin-like 2... | <table><tr><td>Affymetrix ID</td><td>FoldΔ</td><td>GenBank</td><td>Gene</td><td>Gene Description</td></tr><tr><td>1384944_at</td><td>43.3</td><td>BE116855</td><td>Bcl11b</td><td>B-cell leukemia/lymphoma 11B (predicted)</td></tr><tr><td>1370041_at</td><td>11.7</td><td>NM_053440</td><td>Stmn2</td><td>stathmin-like 2</td>... | <table><tr><td>1369213_at</td><td>2.3</td><td>NM_017345</td><td></td><td>neural cell adhesion molecule L1</td></tr><tr><td>1379526_at</td><td>2.3</td><td>BG374506</td><td>Mbp</td><td>Myelin basic protein</td></tr><tr><td>1387424_at</td><td>2.2</td><td>NM_012884</td><td>Cntn2</td><td>contactin 2</td></tr><tr><td>1370124... |
4a455c9cb54bdee3f23cc5883c07f5fbc85b0b8b0412c98ef1ea399dd8d9b7d9.png | simple | <table><tr><td>G6PD Status</td><td>Parasite density/log10 μl</td><td>Hb (g/dl)</td><td>HCT (%)</td><td>MCV (fl)</td><td>MCH (pg)</td><td>MCHC (%)</td></tr><tr><td>Normal</td><td>2.97 ± 1.22</td><td>12.44 ± 2.70</td><td>37.86 ± 8.609</td><td>85.51 ± 6.68</td><td>26.87 ± 5.58</td><td>31.98 &... | <table><tr><td>G6PD Status</td><td>Parasite density/log10 μl</td><td>Hb (g/dl)</td><td>HCT (%)</td><td>MCV (fl)</td><td>MCH (pg)</td><td>MCHC (%)</td></tr><tr><td>Normal</td><td>2.97 ± 1.22</td><td>12.44 ± 2.70</td><td>37.86 ± 8.609</td><td>85.51 ± 6.68</td><td>26.87 ± 5.58</td><td>31.98 ± 2.50</td></tr></table> | <table><tr><td>Deficient</td><td>1.64 ± 1.55</td><td>14.15 ± 3.50</td><td>43.13 ± 10.54</td><td>85.75 ± 5.84</td><td>28.12 ± 4.92</td><td>32.43 ± 1.43</td></tr><tr><td>p-value</td><td>0.000</td><td>0.006</td><td>0.005</td><td>0.834</td><td>0.201</td><td>0.149</td></tr></table> |
58439c96c38191ba333bed0f4e7e3abd581097063d3dad8a672c07d5b5a7c087.png | simple | <table><tr><td>Variables</td><td>Adjusted odds ratio</td><td>95 % confidence interval</td><td><i>P</i></td></tr><tr><td><i>Previous-day aPTT</i><sup>a</sup></td><td></td><td></td><td></td></tr><tr><td>≥46 and ≤55 s</td><td>2.03</td><td>0.68–6.10</td><td>0.30</td></tr><tr><td>≥56 and ≤69 s<... | <table><tr><td>Variables</td><td>Adjusted odds ratio</td></tr><tr><td>Previous-day aPTTa</td><td></td></tr><tr><td>≥46 and ≤55 s</td><td>2.03</td></tr><tr><td>≥56 and ≤69 s</td><td>1.32</td></tr><tr><td>≥70 s</td><td>3.24</td></tr><tr><td>Previous-day anticoagulation</td><td>0.21</td></tr><tr><td>Daily lowest corporeal... | <table><tr><td>95 % confidence interval</td><td>P</td></tr><tr><td></td><td></td></tr><tr><td>0.68–6.10</td><td>0.30</td></tr><tr><td>0.41–4.27</td><td>0.47</td></tr><tr><td>1.11–9.44</td><td>0.03</td></tr><tr><td>0.06–0.52</td><td><0.01</td></tr><tr><td>1.20–2.66</td><td><0.01</td></tr><tr><td>1.01–1.04</td><td><0.01<... |
2290cea8b7ceb9b106ca950bb2d735e8905f7f014e51cdbc702d9ca4c195b243.png | simple | <table><tr><td>Protein identification</td><td>Accession number (UniProtKB/TrEMBL)</td><td>Spot</td><td>Fold</td><td>Mascot score</td><td>Sequence coverage (%)</td><td>Peptide number</td><td>Molecular mass (kDA)</td><td>pI</td></tr><tr><td>gSG6 <sup>SP</sup></td><td>Q9BIH5_ANOGA</td><td>794</td><td>1.8</td><td>14</td><t... | <table><tr><td>Protein identification</td><td>Accession number (UniProtKB/TrEMBL)</td><td>Spot</td><td>Fold</td><td>Mascot score</td><td>Sequence coverage (%)</td><td>Peptide number</td><td>Molecular mass (kDA)</td><td>pI</td></tr><tr><td>gSG6 SP</td><td>Q9BIH5_ANOGA</td><td>794</td><td>1.8</td><td>14</td><td>45.22</td... | <table><tr><td>Protein identification</td><td>Accession number (UniProtKB/TrEMBL)</td><td>Spot</td><td>Fold</td><td>Mascot score</td><td>Sequence coverage (%)</td><td>Peptide number</td><td>Molecular mass (kDA)</td><td>pI</td></tr><tr><td></td><td></td><td>1228</td><td>2.0</td><td>21</td><td>36.83</td><td>21</td><td></... |
0e6867868ed6fa4eca5e5a3eeb3cbdc3340d903a4f1f2cf3bf62b3f21725690a.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Men</td><td></td><td colspan="2">Women</td><td></td></tr><tr><td>Non-NAFLD</td><td>NAFLD</td><td><i>P</i></td><td>Non-NAFLD</td><td>NFALD</td><td><i>P</i></td></tr><tr><td>N</td><td>311</td><td>214</td><td></td><td>876</td><td>610</td><td></td></tr><tr><td>Age, yr</td><td... | <table><tr><td rowspan="2"></td><td colspan="2">Men</td><td></td><td colspan="2">Women</td><td></td></tr><tr><td>Non-NAFLD</td><td>NAFLD</td><td>P</td><td>Non-NAFLD</td><td>NFALD</td><td>P</td></tr><tr><td>N</td><td>311</td><td>214</td><td></td><td>876</td><td>610</td><td></td></tr><tr><td>Age, yr</td><td>56 (44–64)</t... | <table><tr><td rowspan="2"></td><td colspan="2">Men</td><td></td><td colspan="2">Women</td><td></td></tr><tr><td>Non-NAFLD</td><td>NAFLD</td><td>P</td><td>Non-NAFLD</td><td>NFALD</td><td>P</td></tr><tr><td>HDL-cholesterol, mmol/L</td><td>1.39 (1.18–1.58)</td><td>1.22 (1.08–1.40)</td><td><0.001</td><td>1.51 (1.32–1.71)<... |
5b30c04bc3b604851b8564914323e59b3a721ec58bafc793f933fefd68abda63.png | complex | <table><tr><td>Study and reference</td><td colspan="2">Pack-years of smoking</td></tr><tr><td></td><td>Controls (N)</td><td>COPDs (N)</td></tr><tr><td>Bergen cohort from Pillai et al [26]</td><td>19 ± 13*(810)</td><td>32 ± 19*(823)</td></tr><tr><td>Copenhagen City Heart Study from Kaur-Knudsen et al [25]</td>... | <table><tr><td>Study and reference</td><td colspan="2">Pack-years of smoking</td></tr><tr><td></td><td>Controls (N)</td><td>COPDs (N)</td></tr><tr><td>Bergen cohort from Pillai et al [26]</td><td>19 ± 13*(810)</td><td>32 ± 19*(823)</td></tr><tr><td>Copenhagen City Heart Study from Kaur-Knudsen et al [25]</td><td>NR</td... | <table><tr><td>LEUVEN cohort from Lambrechts et al [25]</td><td>42.3 (30.0-50.5) (184)</td><td>40.0 (30.0-57.0) (475)</td></tr><tr><td>NETT/NAS cohorts from Pillai et al [26]</td><td>40 ± 28*(472)</td><td>66 ± 30*(389)</td></tr><tr><td>New Zealand study from Young et al [27]</td><td>40 ± 19*(488)</td><td>47 ± 20*(458)<... |
4da201a6a1f8c062137012821983fd94faa2164279186d9862b5e11745efa9fa.png | complex | <table><tr><td>Variable category</td><td>Characteristics</td><td>n (%)</td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td>90 (51.7)</td></tr><tr><td>Female</td><td>84 (48.3)</td></tr><tr><td rowspan="3">Age category</td><td>< 30</td><td>21 (12.1)</td></tr><tr><td>30–60</td><td>114 (65.5)</td></tr><tr><td>&g... | <table><tr><td>Variable category</td><td>Characteristics</td><td>n (%)</td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td>90 (51.7)</td></tr><tr><td>Female</td><td>84 (48.3)</td></tr><tr><td rowspan="3">Age category</td><td>< 30</td><td>21 (12.1)</td></tr><tr><td>30–60</td><td>114 (65.5)</td></tr><tr><td>> 60</td><t... | <table><tr><td>Variable category</td><td>Characteristics</td><td>n (%)</td></tr><tr><td rowspan="3">Type of diabetic complication</td><td>Retinopathy</td><td>10 (14.1)</td></tr><tr><td>Retinopathy + Neuropathy</td><td>28 (39.4)</td></tr><tr><td>Retinopthy + Neuropathy + Nephropathy</td><td>2 (2.8)</td></tr></table> |
cc36b5bb77061a123d285b5c8e5f0100bd139efd3f73199655121e3398e7b832.png | simple | <table><tr><td>Brand name</td><td>Manufacturing country</td><td>Manufacturing date</td><td>Expiring date</td></tr><tr><td>Ciprocin 500</td><td>Bangladesh</td><td>September 2015</td><td>September 2017</td></tr><tr><td>Beuflox 500</td><td>Bangladesh</td><td>June 2015</td><td>May 2017</td></tr><tr><td>Neofloxacin 500</td>... | <table><tr><td>Brand name</td><td>Manufacturing country</td><td>Manufacturing date</td><td>Expiring date</td></tr><tr><td>Ciprocin 500</td><td>Bangladesh</td><td>September 2015</td><td>September 2017</td></tr><tr><td>Beuf</td><td>Banglad</td><td>June 2</td><td>Ma</td></tr></table> | <table><tr><td>Brand name</td><td>Manufacturing country</td><td>Manufacturing date</td><td>Expiring date</td></tr><tr><td>lox 500</td><td>esh</td><td>015</td><td>y 2017</td></tr><tr><td>Neofloxacin 500</td><td>Bangladesh</td><td>August 2015</td><td>August 2018</td></tr><tr><td>Ciprox 500</td><td>Bangladesh</td><td>Augu... |
50680eb815c177f04804e6eb3713b85968767d72c0045b33a287dd8eeb898a21.png | simple | <table><tr><td>Compounds</td><td>Street</td><td>Alley</td><td>Relative Difference <sup>a</sup> (%)</td><td>Wilcoxon <i>p</i>-Value <sup>b</sup></td><td>Correlation Coefficient <sup>c</sup></td></tr><tr><td>Σ<sub>8</sub>PAH<sub>semivolatile</sub></td><td>20.59 (24.00 ± 15.49)</td><td>17.46 (20.81 ± 14.04)... | <table><tr><td>Compounds</td><td>Street</td><td>Alley</td><td>Relative Difference a (%)</td><td>Wilcoxon p-Value b</td><td>Correlation Coefficient c</td></tr></table> | <table><tr><td>Σ8PAHsemivolatile</td><td>20.59 (24.00 ± 15.49)</td><td>17.46 (20.81 ± 14.04)</td><td>16</td><td>0.002</td><td>0.93 ***</td></tr><tr><td>Pyrene</td><td>0.89 (0.94 ± 0.34)</td><td>0.83 (0.89 ± 0.33)</td><td>7</td><td>0.198</td><td>0.90 ***</td></tr><tr><td>Phe</td><td>15.50 (18.32 ± 12.35)</td><td>12.63 (... |
4aa3c026a8a09acb4185e7191ab99c7d80f6196599858b05215cbcf7f125f44b.png | complex | <table><tr><td></td><td colspan="2">All subjects [<i>n</i> (%)]</td><td colspan="2">Subjects assessed as unexposed or probably exposed to TCE [<i>n</i> (%)]</td></tr><tr><td>Characteristics</td><td>Controls (<i>n</i> = 982)</td><td>Cases (<i>n</i> = 1,189)</td><td>Controls (<i>n</i> = 566)</td><td>Cases (<i>n</i> = 644... | <table><tr><td></td><td colspan="2">All subjects [n (%)]</td><td>Subjects assessed as unexposed or probably exposed to TCE [n (%)]</td></tr><tr><td>Characteristics</td><td>Controls (n = 982)</td><td>Cases (n = 1,189)</td><td>Controls (n = 566)</td></tr><tr><td colspan="4">Age at reference date (years)</td></tr><tr><td>... | <table><tr><td>Subjects assessed as unexposed or probably exposed to TCE [n (%)]</td></tr><tr><td>Cases (n = 644)</td></tr><tr><td>Age at reference date (years)</td></tr><tr><td>56 (8.7)</td></tr><tr><td>83 (12.9)</td></tr><tr><td>115 (17.9)</td></tr><tr><td>174 (27.0)</td></tr><tr><td>216 (33.5)</td></tr><tr><td>Sex</... |
8f5c0dbb9a11802364dd3ba90c1fc960f6db54765d1ecf4de1d0f5f4f484fc1e.png | simple | <table><tr><td>Information</td><td>Number of bits</td></tr><tr><td>Outgoing neighbours</td><td>4</td></tr><tr><td>Hash function number</td><td>3</td></tr><tr><td>Quotient value</td><td>33</td></tr></table> | <table><tr><td>Information</td><td>Number of bits</td></tr><tr><td>Outgoing neighbours</td><td>4</td></tr></table> | <table><tr><td>Information</td><td>Number of bits</td></tr><tr><td>Hash function number</td><td>3</td></tr><tr><td>Quotient value</td><td>33</td></tr></table> |
c555bcf0f691552b3b731951d8d5f0b31a629820edaad6ecf1df99d8a72a231c.png | complex | <table><tr><td></td><td></td><td colspan="3">(<i>α</i>/<i>β</i>)<sub><i>x</i></sub> = 2 Gy</td><td colspan="3">(<i>α</i>/<i>β</i>)<sub><i>x</i></sub> = 10 Gy</td></tr><tr><td>Patient</td><td>Model</td><td>minRBE</td><td>maxRBE</td><td>meanRBE</td><td>minRBE</td><td>maxRBE</td><td>meanRBE</td></tr><t... | <table><tr><td></td><td></td><td colspan="3">(α/β)x = 2 Gy</td><td colspan="3">(α/β)x = 10 Gy</td></tr><tr><td>Patient</td><td>Model</td><td>minRBE</td><td>maxRBE</td><td>meanRBE</td><td>minRBE</td><td>maxRBE</td><td>meanRBE</td></tr><tr><td>1</td><td rowspan="2">LEMDt = 10 Gy</td><td>1.10</td><td>1.70</td><td>1.19</td... | <table><tr><td>2</td><td>CAR</td><td>1.23</td><td>1.43</td><td>1.28</td></tr></table> |
442c83d5ba99066bc77b3983c4b738b3e8b2100b3375a415d1d96e62b4d78c5f.png | simple | <table><tr><td>Inclusion</td><td>Exclusion</td></tr><tr><td>Severe illness requiring intensive care</td><td>Substituted hypothyroidism (E03.0, E03.1, E03.3 E03.9, E89.0) or substitution in case of thyroid carcinoma (C73)</td></tr><tr><td>Stay of at least 24 hours at the ICU</td><td>Hyperthyroidism treated with thyrosta... | <table><tr><td>Inclusion</td><td>Exclusion</td></tr><tr><td>Severe illness requiring intensive care</td><td>Substituted hypothyroidism (E03.0, E03.1, E03.3 E03.9, E89.0) or substitution in case of thyroid carcinoma (C73)</td></tr><tr><td>Stay of at least 24 hours at the ICU</td><td>Hyperthyroidism treated with thyrosta... | <table><tr><td>Manifest AIDS disease (B24)</td></tr><tr><td>Pregnancy</td></tr></table> |
4696bc73a27bb9c338f8db4ffed48e15fb8eb3debfb2bc277b04fc251ac00add.png | complex | <table><tr><td rowspan="3">Variables</td><td colspan="5">Coefficient (95 % CI)</td></tr><tr><td rowspan="2">Gamma</td><td rowspan="2">Linear</td><td colspan="3">Quantile</td></tr><tr><td>Quantile 0.25</td><td>Quantile 0.50</td><td>Quantile 0.75</td></tr><tr><td>Age</td><td>0.15 (0.14, 0.17)</td><td>0.15 (0.13, 0.17)</t... | <table><tr><td rowspan="3">Variables</td><td colspan="5">Coefficient (95 % CI)</td></tr><tr><td rowspan="2">Gamma</td><td rowspan="2">Linear</td><td colspan="3">Quantile</td></tr><tr><td>Quantile 0.25</td><td>Quantile 0.50</td><td>Quantile 0.75</td></tr><tr><td>Age</td><td>0.15 (0.14, 0.17)</td><td>0.15 (0.13, 0.17)</t... | <table><tr><td colspan="6">Consumption of fried foodf</td></tr><tr><td>1–3×/month</td><td>1.00 (0.41, 1.58)</td><td>1.06 (0.42, 1.71)</td><td>0.93 (0.26, 1.61)</td><td>0.90 (0.25, 1.55)</td><td>0.99 (0.02, 1.96)</td></tr><tr><td>1–3×/week</td><td>1.22 (0.64, 1.80)</td><td>1.27 (0.62, 1.91)</td><td>0.86 (0.20, 1.52)</td... |
1be8e5cb5f43071ccf8bc8f776bc81db04313cee0ef821506670f8bb4c1eaab6.png | simple | <table><tr><td> </td><td>Group A</td><td>Group B</td></tr><tr><td><i>Symptoms score (NIH-CPSI questionnaire 0–43) (±S.D.)</i></td><td> </td><td> </td></tr><tr><td>Baseline</td><td>21.85 ± 5.23</td><td>22.56 ± 5.78</td></tr><tr><td>2 months</td><td>12.00 ± 4.34</td><td>5.23 ± 2.76</td></tr... | <table><tr><td></td><td>Group A</td><td>Group B</td></tr><tr><td>Symptoms score (NIH-CPSI questionnaire 0–43) (±S.D.)</td><td></td><td></td></tr><tr><td>Baseline</td><td>21.85 ± 5.23</td><td>22.56 ± 5.78</td></tr><tr><td>2 months</td><td>12.00 ± 4.34</td><td>5.23 ± 2.76</td></tr><tr><td>4 months</td><td>10.48 ± 4.14</t... | <table><tr><td></td><td>Group A</td><td>Group B</td></tr><tr><td>6 months</td><td>13.26 ± 4.88</td><td>3.67 ± 1.98</td></tr><tr><td>Pain score (NIH-CPSI questionnaire 0–21) (±S.D.)</td><td></td><td></td></tr><tr><td>Baseline</td><td>11.65 ± 3.23</td><td>12.00 ± 2.78</td></tr><tr><td>2 months</td><td>6.20 ± 2.35</td><td... |
6ff0245864e203ae6a4d17fe3d7da1710bf370316bdf69ba152b9fca037527f4.png | simple | <table><tr><td>Candidates</td><td>Anatomical evidence to ARC or <i>Kiss1</i> neurons</td><td>ICV or electrophysiology studies</td><td>Receptors expressed in <i>Kiss1</i> neurons</td><td>Physiological relevance</td></tr><tr><td>Agouti-related peptide/neuropeptide Y (AgRP/NPY)</td><td>AgRP neurons formed synaptic connect... | <table><tr><td>Candidates</td><td>Anatomical evidence to ARC or Kiss1 neurons</td><td>ICV or electrophysiology studies</td><td>Receptors expressed in Kiss1 neurons</td><td>Physiological relevance</td></tr><tr><td>Agouti-related peptide/neuropeptide Y (AgRP/NPY)</td><td>AgRP neurons formed synaptic connections with Kiss... | <table><tr><td>Leptin</td><td></td><td>ICV leptin treatment to fasted adult rats increased LH pulse frequency, amplitude, and mean levels (140)</td><td>Lepr (83, 141)</td><td>Kiss1 neurons are indirect target of leptin during puberty onset (142)</td></tr><tr><td>Neurokinin B (NKB)</td><td>NKB-immunoreactive fibers in c... |
4425ea195c27762dce30d0c32d3ae068376f0ebdc40cc5bddcd78bbcdb74fa45.png | simple | <table><tr><td><i>Body Site</i></td><td><i>TPS Technique</i></td><td><i>Energy</i></td></tr><tr><td>Brain</td><td>3D</td><td>6 MV, 6 MV FFF</td></tr><tr><td>Brain</td><td>IMRT, VMAT</td><td>6 MV</td></tr><tr><td>Whole Brain</td><td>3D</td><td>6 MV</td></tr><tr><td>Head and Neck bilateral</td><td>3D, IMRT, VMAT</td><td>... | <table><tr><td>Body Site</td><td>TPS Technique</td><td>Energy</td></tr><tr><td>Brain</td><td>3D</td><td>6 MV, 6 MV FFF</td></tr><tr><td>Brain</td><td>IMRT, VMAT</td><td>6 MV</td></tr><tr><td>Whole Brain</td><td>3D</td><td>6 MV</td></tr><tr><td>Head and Neck bilateral</td><td>3D, IMRT, VMAT</td><td>6 MV</td></tr></table... | <table><tr><td>Body Site</td><td>TPS Technique</td><td>Energy</td></tr><tr><td>Lung ‐ Left upper lobe</td><td>3D, IMRT</td><td>6 MV</td></tr></table> |
3dd5d951cd61d3022bdf1e3d8b5bc18552dbcea0c2a421e2002f5fe55f99e9df.png | simple | <table><tr><td>Peak <sup>a</sup></td><td>Carotenoid</td><td><i>t</i><sub>R </sub><sup>b</sup> (min)</td><td>λ<sub>max</sub><sup> c</sup> (nm)</td><td>% III/II</td><td>% A<sub>B</sub>/A<sub>II</sub></td><td>[M + H]<sup>+ </sup>(<i>m/z</i>)</td><td>MS/MS fragment ions (positive mode) (<i>m/z</i>)</td><td>[M − ... | <table><tr><td>Peak a</td><td>Carotenoid</td><td>tR b (min)</td><td>λmax c (nm)</td><td>% III/II</td><td>% AB/AII</td><td>[M + H]+ (m/z)</td><td>MS/MS fragment ions (positive mode) (m/z)</td><td>[M − H]− (m/z)</td><td>MS/MS fragment ions (negative mode)(m/z)</td></tr><tr><td>26</td><td>crustaxanthin</td><td>7.9</td><td... | <table><tr><td>27</td><td>crustaxanthin</td><td>8.5</td><td>422, 449, 476</td><td>35</td><td>0</td><td>601</td><td>583 [M + H − 18]+, 565 [M + H − 18 − 18]+, 547 d [M + H − 18 − 18 − 18]+, 509 [M + H − 92]+</td><td>599</td><td>581 [M − 18]−, 563 [M − 18 − 18]−, 545 [M − 18 − 18 − 18]−, 507 [M − 92]−</td></tr><tr><td>28... |
d3e8f70e60982a81ff4666d98f1f1f79025dad9bbd1ad48027947f37056a0053.png | simple | <table><tr><td>Characteristic</td><td>Variable</td><td>Case</td></tr><tr><td>Gender</td><td>Male</td><td>24165</td></tr><tr><td></td><td>Female</td><td>19825</td></tr><tr><td>Site</td><td>Colon</td><td>23563</td></tr><tr><td></td><td>Rectal</td><td>20427</td></tr><tr><td>Colon</td><td>Proximal</td><td>7588</td></tr><tr... | <table><tr><td>Characteristic</td><td>Variable</td><td>Case</td></tr></table> | <table><tr><td>Gender</td><td>Male</td><td>24165</td></tr><tr><td></td><td>Female</td><td>19825</td></tr><tr><td>Site</td><td>Colon</td><td>23563</td></tr><tr><td></td><td>Rectal</td><td>20427</td></tr><tr><td>Colon</td><td>Proximal</td><td>7588</td></tr><tr><td></td><td>Distal</td><td>7305</td></tr><tr><td></td><td>un... |
d2e1262234bdf1328f646c381565bf9dfb5b153e8af0cf8c01430e9ac293b188.png | simple | <table><tr><td> </td><td>MetS present (n = 37)</td><td>MetS absent (n = 38)</td><td>p</td></tr><tr><td>Age (years)</td><td>47 ± 6</td><td>40 ± 8</td><td><0.001</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>30.9 (24.2-42.5)</td><td>23.4 (17.6-29.8)</td><td><0.001</td></tr><tr><td>Waist circ... | <table><tr><td></td><td>MetS present (n = 37)</td><td>MetS absent (n = 38)</td><td>p</td></tr><tr><td>Age (years)</td><td>47 ± 6</td><td>40 ± 8</td><td><0.001</td></tr><tr><td>Body mass index (kg/m2)</td><td>30.9 (24.2-42.5)</td><td>23.4 (17.6-29.8)</td><td><0.001</td></tr><tr><td>Waist circumference (cm)</td><td>107.0... | <table><tr><td></td><td>MetS present (n = 37)</td><td>MetS absent (n = 38)</td><td>p</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>88 ± 9</td><td>74 ± 6</td><td><0.001</td></tr><tr><td>Total cholesterol (mmol/L)</td><td>5.25 ± 0.74</td><td>4.38 ± 0.80</td><td><0.001</td></tr><tr><td>Low-density lipoprotein c... |
6856ec8a09bfb43ae905e3e09c908ee4bd86afb3ed4fabda6c8a70dd628e4844.png | complex | <table><tr><td>Sample</td><td>Source</td><td>UId</td><td>Sex</td><td>Age</td><td colspan="4">Mutation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>nt change</td><td>aa change</td><td>domain affected</td><td>type of mutation</td></tr><tr><td>RTT1</td><td>HBTRC</td><td>4315</td><td>F</td><td>11</td><td>c... | <table><tr><td>Sample</td><td>Source</td><td>UId</td><td>Sex</td><td>Age</td><td colspan="4">Mutation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>nt change</td><td>aa change</td><td>domain affected</td><td>type of mutation</td></tr><tr><td>RTT1</td><td>HBTRC</td><td>4315</td><td>F</td><td>11</td><td>c... | <table><tr><td>Sample</td><td>Source</td><td>UId</td><td>Sex</td><td>Age</td><td colspan="4">Mutation</td></tr><tr><td>RTT9</td><td>BCM</td><td>93-244</td><td>F</td><td>4</td><td>c.750insC</td><td>P251fs</td><td>TRD</td><td>Frameshift/Truncation</td></tr><tr><td>CON4</td><td>NSWTRC</td><td>88210</td><td>F</td><td>43</t... |
c59ff8e8f2ad04deea8fdaedfc62bcbeb824eef6e94ff5400e65d8162c81114a.png | complex | <table><tr><td rowspan="2">Question</td><td colspan="4">HCW category Total, (%)</td><td></td></tr><tr><td>MDs (<i>n</i> = 20)</td><td>Nurses (<i>n</i> = 77)</td><td>PA (<i>n</i> = 4)</td><td>Overall (<i>n</i> = 101)</td><td>χ<sup>2</sup>, <i>p</i>-value</td></tr><tr><td colspan="5">Whether facility is equipped to ... | <table><tr><td rowspan="2">Question</td><td>HCW category Total, (%)</td></tr><tr><td>MDs (n = 20)</td></tr><tr><td colspan="2">Whether facility is equipped to handle EVD cases</td></tr><tr><td>Yes</td><td>4 (3.96)</td></tr><tr><td>No</td><td>14 (13.86)</td></tr><tr><td>I don’t know</td><td>2 (1.98)</td></tr><tr><td col... | <table><tr><td colspan="3">HCW category Total, (%)</td><td></td></tr><tr><td>Nurses (n = 77)</td><td>PA (n = 4)</td><td>Overall (n = 101)</td><td>χ2, p-value</td></tr><tr><td colspan="3">Whether facility is equipped to handle EVD cases</td><td>2.66, 0.62</td></tr><tr><td>21 (20.79)</td><td>1 (0.99)</td><td>26 (25.74)</... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.